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Background:  Atherosclerosis, endothelial dysfunction and inflammation are thought to be key 
pathophysiologic processes in preeclampsia. The basic thesis of this dissertation is that maternal 
infections may trigger upregulation of proinflammatory cytokines in women with preeclampsia 
resulting in vascular injury. 
Objectives: We evaluated the evidence for a potential infectious disease etiology for 
preeclampsia in three papers.  
Methods: For the first paper, we conducted a 1:3 matched case control study. In this study we 
measured immunoglobulin G (IgG) antibodies to HSV-1, HSV-2, CMV, and EBV in serum 
samples obtained from 50 cases with preeclampsia and 150 normotensive controls, matched on 
age, parity and race. For the second paper, we conducted a comprehensive review of published 
studies that explored the association between both bacterial and viral infections, and examined 
the strength of this association. For the third paper, we investigated the association between self-
reported Genital Warts (HPV), Genital Herpes (HSV-2), Chlamydia (C. trachomatis), Gonorrhea 
(N. gonorrhoeae) infections, sociodemographic, and behavioral risk factors and the risk of 
preeclampsia in a representative national sample of 10,847 reproductive age women. 
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Results: We found that seroconversion for HSV 1 /2 or CMV was associated with a five-fold 
increased risk for developing preeclampsia (OR 5.4, 95% CI 1.0-29.0) after adjusting for 
education, income, smoking, years of cohabitation, medical insurance, and type of birth control.  
Pooling of relevant epidemiologic data, also revealed a two-fold increased risk of preeclampsia 
associated with bacterial and viral infections (OR 2.1, 95% CI 1.8-2.6). Additionally, population-
based results suggest that Genital Warts, Genital Herpes, and C. trachomatis significantly 
increased the risk of preeclampsia (OR 3.0, 95% CI 1.0-8.8; OR 7.4, 95% CI 1.4-47.4; OR 5.2, 
95% CI 1.3-20.2, respectively), after adjusting for socio-demographic, behavioral, and infection-
related risk factors.  
Public Health Relevance: Given the widespread prevalence of these infections, and the 
potential to prevent infection, our findings have important public health implications in the 
context of potential preventive strategies and identification of high-risk individuals. 
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1. INTRODUCTION 
 
During pregnancy, a woman’s body undergoes a number of physiological adjustments in order to 
provide for the growth and development of her fetus, while at the same time maintaining 
homeostasis. Every organ system is affected, including her immune system. Concurrently, the 
fetus is an active participant in trans-placental exchange of resources by altering its own 
development as its regulatory processes matures. The physiological tug of war that ensues is 
complex, interrelated, and changes constantly throughout pregnancy. Any aberration to this 
system can adversely affect the progress and outcome of the pregnancy. Such an aberration is 
found in women who develop preeclampsia.  
The American College of Obstetrics and Gynecology (ACOG) defines preeclampsia as a 
systolic blood pressure greater than 140 mmHg or a diastolic blood pressure greater than 90 
mmHg accompanied by proteinuria of 300 mg/24 hr urine collection, or more than 2+ on a 
voided or 1+ on a cathetherized random urine specimen, in a previously normotensive woman. In 
the past, a major weakness in the preeclampsia literature has been the lack of a gold standard 
definition for preeclampsia. This is illustrated by a preeclampsia literature that is saturated with 
diverse terminologies to describe this disorder. For example, terms such as toxemia, pregnancy 
induced hypertension, preeclampsia, and preeclamptic toxemia, have all been used in the 
literature to describe hypertension in pregnancy.(32) Lack of universal agreement on preeclampsia 
diagnosis has significantly increased the likelihood of case misclassification, and may have led to 
 varying measures of strength of association between exposure and disease across studies, even 
among those studies evaluating identical parameters. 
Furthermore, preeclampsia researchers have primarily focused on characterizing 
physiological processes in patients known to have preeclampsia, but unfortunately, it has been 
impossible to determine whether these processes cause preeclampsia or are the result of the 
disease itself. In addition, many early investigations were retrospective and thus were not able to 
establish the nature of the relationship between risk factor and disease. Nevertheless, many 
theories of probable causes have emerged over the years, but unfortunately, some were not 
grounded in sound biological principles. In order to prevent a disease, it is necessary to know 
what the etiology and pathogenesis of the disease is and whether there are methods and tools to 
help predict what population is at greater risk.  
Preeclampsia is distinguished from other hypertensive disorders of pregnancy such as 
chronic hypertension and gestational hypertension, by the presence of protein in the urine. In the 
past, known risk factors associated with proteinuria, including diabetes, smoking and obesity, 
were not controlled for in some studies of preeclampsia pathogenesis. In addition, it is now 
recognized that preeclampsia is not a one-disease disorder, but rather a clinical syndrome. The 
possibility that several factors interact to cause this disorder further complicates efforts to find 
both its prevention and cure. 
Atherosclerosis, inflammation and endothelial dysfunction have been suggested as central 
to the pathogenesis of preeclampsia. The observed inflammatory response in both diseases may 
be induced by a number of factors. For example, Syndrome X (adiposity, hyperinsulinemia, 
hyperglycemia, and elevated blood pressure) is now strongly implicated in both diseases, (33) and 
syndrome X involves inflammation.(45) (158) Pro-inflammatory mediators may also be induced by 
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 infection. Because some infectious diseases are highly prevalent in the general population, 
pregnant women will continue to be at risk for acquiring new infections during pregnancy. For 
example, herpes virus infections such as HSV-1 and HSV-2, or CMV establish lifelong 
persistent asymptomatic infections, and if acquired during pregnancy can cause a number of 
adverse pregnancy outcomes such as, neonatal herpes, intrauterine growth restriction (IUGR), 
miscarriage, and preterm labor.  
Endothelial dysfunction and excessive inflammation are common occurrences in 
preeclampsia, and we know that infection clearly triggers an inflammatory response in infected 
hosts. So, taken together, it is reasonable to suggest that for at least some of the pathways 
preceding onset of preeclampsia, that infectious agents may be contributing factors. Therefore, 
the basic thesis of this dissertation is that maternal infections may stimulate upregulation of 
proinflammatory cytokines in preeclamptic pregnancies, resulting in vascular injury. If this thesis 
is correct, then, the infectious disease hypothesis for preeclampsia, like that of atherosclerosis, 
could be pursued more intensely. But more appropriately, the knowledge gained from continued 
research may be of widespread usefulness in understanding the pathogenesis of preeclampsia, 
and may lead to development of preventive and therapeutic strategies in the future. 
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2. BACKGROUND 
 
2.1.     DIAGNOSIS AND CLASSIFICATION 
An important consideration in classifying hypertensive disorders of pregnancy is the 
differentiation between pre-pregnancy hypertension and new onset hypertension. There are 
currently four different types of pregnancy-associated hypertensive disorders (Table 1): 1) 
pregnancy-associated hypertension; 2) pre-existing hypertension; 3) preeclampsia superimposed 
upon chronic hypertension; and 4) eclampsia. 
Table 1: Classification of Hypertensive Disorders of Pregnancy 
 
DISORDER DEFINITION INCIDENCE 
Pregnancy-associated 
hypertension 
New onset hypertension that occurs 
after 20 weeks of gestation and 
settles within 6 weeks of delivery, 
characterized by a rise in blood 
pressure to >140/90 mmHg 
6-7% of pregnancies 
 
 
 
2-8% of pregnancies 
Hypertension with 
proteinuria(>0.3 
g/day) 
Pre-existing hypertension Chronic hypertension diagnosed 
before pregnancy or earlier than 20 
weeks of gestation, and persisting 
after delivery, characterized by a 
rise in blood pressure to >140/90 
mmHg 
3-5% of pregnancies 
Preeclampsia 
superimposed on chronic 
hypertension 
As Above 15-25% of 
hypertensive 
pregnancies 
Eclampsia Generalized convulsion during 
hypertensive pregnancy, labor, or 
within 7 days of delivery 
0.05% of pregnancies 
Source: Data from Mortl MG and Schneider MC 2000 , Walker JJ.2000 (modified table). 
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Gestational hypertension is defined as a systolic blood pressure >140 mmHg or diastolic 
blood pressure >140 mmHg that develops before 20th week of gestation without the occurrence 
of proteinuria, and is generally considered benign.(66) This diagnosis is nonspecific and can 
include women who may eventually develop preeclampsia and women who manifest 
preeclampsia symptoms without proteinuria. Final diagnosis is made after delivery when it is 
determined whether the woman had preeclampsia.(203)   
Preeclampsia is defined as a systolic blood pressure greater than 140 mmHg or diastolic 
blood pressure greater than 90 mmHg after 20th weeks gestation in a previously normotensive 
woman, and the occurrence of proteinuria in the last three or four weeks of pregnancy. 
Proteinuria is defined as urinary excretion of protein (≥ 0.3 g) in a 24-hr specimen. 
Chronic hypertension is defined as systolic blood pressure ≥ 140 mmHg, diastolic 
pressure ≥ 90 mmHg, or both that occurred before pregnancy and is present before 20th week of 
gestation, or persists longer than 12 weeks postpartum. 
Preeclampsia superimposed on chronic hypertension is diagnosed when a woman with 
chronic hypertension develops new onset proteinuria after 20th weeks of gestation.  
Eclampsia occurs in a woman whose preeclampsia has advanced to a more severe stage 
and involves seizures that cannot be attributed to other causes. 
The incidence of preeclampsia among chronic hypertensive and gestational hypertensive 
pregnancies are 3 to 5 percent and 6 percent respectively. (106) The incidence of preeclampsia 
appears to have increased in recent years. This is likely due to an increase in numbers of 
pregnancies among older women, and a rise in numbers of multiple births, both of which are 
associated with high risk of preeclampsia. For example, according to the National Center for 
Health Statistics, in 1998, birth rates among women ages 30-44 and number of births to women 
 15
 45 and older reached the highest levels in 30 years. In addition, overall twin births increased 
almost 50%, and significantly larger increases were observed in women ages 45 to 49. (190)
In contrast, the incidence of eclampsia (0.05%) has declined considerably in the past 
several decades. Data from the United Kingdom (52) indicate a 20-fold decline in eclampsia 
incidence since 1922. Similarly, data from Australia, and New Zealand, (39) show declines in 
eclampsia incidence occurring between the years 1928 and 1933 (3.2/1000), and from 1956 to 
1958 (0.8/1000). This decline is primarily an artificial one and reflects the practice of early 
delivery or cesarean sections required in most preeclamptic pregnancies. Early delivery and 
cesarean sections have made it significantly less likely that pregnancies complicated by 
preeclampsia will progress to eclampsia.  
 
2.2.     CHALLENGES IN PREECLAMPSIA RESEARCH 
A major challenge confronting researchers and practitioners is the fundamental philosophy that 
forms the guiding force in their respective disciplines, that is, the conduct of research versus 
delivery of patient care. For example, preeclampsia diagnostic criteria have in recent years taken 
either a restrictive or an inclusive approach. Restrictive diagnostic criteria, consider both new 
onset hypertension after 20 weeks and the presence of proteinuria greater than 3 g/24 hours. The 
inclusive approach, on the other hand, takes a much broader approach in defining preeclampsia. 
Proponents of the inclusive concept argue that diagnosis should factor in the multi-systemic 
nature of the disease and monitor the whole spectrum of symptoms and organs affected. 
Although it may be justifiable for clinicians to adopt an inclusive approach in clinical practice, a 
more restrictive approach is likely to reduce misclassification bias that may be introduced with 
an inclusive classification system. Resolving the conflicts posed by the two extremes of the 
 16
 diagnostic spectrum, especially in the context of misclassification bias, is a critical factor that 
may ultimately affect translation of research findings into clinical practice. 
The lack of consistency in defining preeclampsia has led to major confusion and 
disagreement among investigators. Discrepancies in hypertension classification have invariably 
revolved around whether or not proteinuria was included in the diagnosis of preeclampsia. For 
example in a review by Chappell and colleagues, (30) 73 journal articles were evaluated for a 
preeclampsia definition. Of the 73 journal articles, 67 used a general definition of preeclampsia. 
Of these 67 articles, 47 included a definition of preeclampsia, but the definitions varied 
considerably. Clear definition of preeclampsia that is uniformly used may prevent inclusion of 
patients who do not have preeclampsia or patients whose diagnoses are unclear. But most 
importantly, a standardized preeclampsia classification system will make comparisons between 
studies possible. 
  Some studies used diastolic BP and systolic BP inconsistently in the diagnosis. With the 
exception of one study, which used a blood pressure threshold of greater than 145/85 mmHg, 
most used a threshold of 140 mmHg for SBP and 90 mmHg for DBP. Finally, proteinuria 
measurement varied from study to study as well. Twenty nine articles used a proteinuria 
measurement of 0.3 gr/24 hr, 4 articles used 0.5 gr/24 hr, and others used dipstick analysis 
alone.(30) Dipstick measurements of protein in the urine have not been found to correlate well 
with 24-hour urinary collection protein excretion values in pregnant women.(120)(95) Such 
inconsistencies have resulted in considerable disparities in incidence numbers among studies.  
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 2.3.     EPIDEMIOLOGY: PREECLAMPSIA INCIDENCE 
Preeclampsia occurs in 3-10% of all pregnancies world-wide and in approximately 2-8% in the 
United States. (44) (79) Incidence varies depending on institution, diagnostic criteria, and patient 
population. For example, in a summary of a national hospital discharge database, the rate of 
preeclampsia was 2.6% and 0.6% for eclampsia, (155) whereas the Maternal Fetal Medicine 
Network trial of low-dose aspirin in preeclampsia estimated a 6.3% incidence of 
preeclampsia.(169) Disparity in preeclampsia incidence often stems from the use of hospital 
discharge diagnoses. In a validation study conducted by Ales and Charleson,(4) 25% of 
preeclampsia diagnoses were incorrectly determined by ICD9 codes, and 53% of ICD9 coding 
missed true preeclampsia diagnoses. In the case of The Maternal Fetal Network trial, only 
primiparous women were included despite the fact that they are five times more likely to develop 
preeclampsia in comparison to multiparous women. (114)  
Disparities in incidence figures can also be the result of inclusion of women with 
superimposed preeclampsia or women with underlying maternal disease such as, chronic 
hypertension and diabetes mellitus. Inclusion of a higher risk population may significantly 
increase incidence estimates. In fact, underlying maternal morbidity may account for 20% to 
40% of preeclampsia. (32)(110)(171) Moreover, mothers with underlying maternal disease may be 
better able to navigate the healthcare system, and possibly may have been over-represented in 
maternal and perinatal morbidity statistics. (129)   
As of February 2004, 281 patients (including primiparous and multiparous gravidas) 
enrolled in the Prenatal Exposures and Preeclampsia Prevention (PEPP) project at Pittsburgh’s 
Magee-Womens Hospital had a discharge diagnosis of preeclampsia. The overall rate of 
preeclampsia is 6.9% (205/2955) among nulliparous and 2.6% (76/2955) among multiparous 
women delivering at Magee. Magee’s total obstetrical population comes from two sources: 1) 
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 Magee’s prenatal clinics (longitudinal cohort, N= 2211), and 2) private physician practices 
(crosssectional cohort, N= 744). The incidence of preeclampsia among nulliparous patients in the 
longitudinal cohort is 1.4% (31/2211). In contrast, the incidence of preeclampsia among the cross 
sectional participants is 23.4% (174/744). These contrasting incidence numbers clearly 
demonstrate that preeclampsia rates can vary widely depending on which subgroup of the 
population is being studied.      
In comparison to preeclampsia incidence figures generally reported in the literature (3-10%), the 
incidence at Magee is significantly lower (1.4%) among nulliparous patients. This is likely a 
reflection of Magee’s strict diagnostic criteria or due to characteristics of the patient population. 
Patients who volunteer to participate in research studies at Magee may be different from the 
general population on important characteristics that may affect preeclampsia incidence rates. 
  
2.4.     EPIDEMIOLOGY: PREECLAMPSIA RISK FACTORS 
Preeclampsia is a serious complication of pregnancy affecting primarily first pregnancies. Other 
risk factors include multiple gestation pregnancies, previous history of preeclampsia, maternal 
age < 20 and >35, race, family history, chronic hypertension, obesity, and diabetes. 
(196)(44)(168)(169)(3)
2.4.1. Primiparity 
 
Primiparous women have consistently been found to be at significant risk for developing 
preeclampsia, whereas multiparous women with no previous history of the disease are rarely 
affected. For example, MacGillivray found a preeclampsia incidence of 5.6% among nulliparas 
and only a 0.3% incidence among multiparas in a Scotish cohort consisting of 5,878 women.(114) 
In another population study, Seidman and colleagues reported a 2.8% preeclampsia incidence in 
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 a cohort of 5,591 nulliparous Israeli women. (164) At present, it is still not clear why primiparous 
women are more likely to develop preeclampsia. Because preeclampsia is a disease of 
placentation, it is possible that first pregnancy placentation may be distinctive enough to be a 
potentially relevant factor in the origin of this disease. 
 In summary, numerous studies have consistently implicated primiparity as a major risk 
factor for preeclampsia.   
2.4.2. Multiple Gestation Pregnancies 
Maternal conditions associated with excessive placental size, such as multiple gestation 
pregnancies, (26) hydatidiform moles, (135) and hydrops fetalis (163) have all been implicated with 
an elevated risk for preeclampsia. Zhang et al, in an analysis of pooled results from 6 studies of 
the relationship between multiple gestation pregnancies and the risk of preeclampsia, found that 
in comparison to singleton pregnancies, women with twin pregnancies were three times more 
likely to develop preeclampsia.(205) In a review of a population databank from Scotland, (27) the 
impact of parity on the risk of preeclampsia was evaluated. Among twin gestations, both 
primiparous (OR 3.41, 95% CI 2.9-4.1) and multiparous women (OR 7.29, 95% CI 6.0-8.9) were 
at increased risk of developing preeclampsia. Similarly, in a population-based cohort study 
(N=3407), Coonrod et al found that among twin gestations, the risk of preeclampsia was 4 times 
higher in nulliparous compared to multiparous women.(38) The same study suggested that 
advanced maternal age coupled with multi-fetal gestations significantly increased the risk of 
preeclampsia.  
A recent analysis of prospective data from two trials of low-dose aspirin use found that 
women with twin pregnancies (N=684) were twice more likely to develop preeclampsia (RR 
2.48, 95% CI 1.82-3.38), when compared to singleton gestation pregnancies (N=2946). This 
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 finding tends to hold true even after adjustments for age, race, mean arterial pressure (MAP), and 
smoking. (169)
Thus, the epidemiologic evidence so far suggests that multiple gestation pregnancies are 
at significantly higher risk of preeclampsia compared to singleton pregnancies. 
2.4.3. Previous History of Preeclampsia 
Women who experienced preeclampsia in a previous pregnancy are at substantially increased 
risk of preeclampsia in subsequent pregnancies. For example, Lie and colleagues reported a 1.7% 
risk of preeclampsia among second pregnancies in a Norwegian population-based study of 
women with no prior history of preeclampsia. (108) If women had preeclampsia in the first 
pregnancy, risk was substantially increased (13.1%). Furthermore, the risk of preeclampsia in a 
subsequent pregnancy was higher with increasing severity of the disease, and particularly high if 
preeclampsia developed before 30 weeks’ gestation (47) in the index pregnancy. In a prospective 
investigation conducted by Sibai and colleagues, out of 125 women with severe preeclampsia in 
the second trimester, 35% had normal blood pressure during a subsequent pregnancy and almost 
twice as many (65%) developed preeclampsia. Furthermore, of those who developed 
preeclampsia one third developed preeclampsia at ≤ 27 weeks, one third at 28 to 36 weeks, and 
another one third at ≥ 37 weeks. (166)
Visser et al found that the severity of preeclampsia was also related to levels of 
proteinuria. For example increases in proteinuria of 0.3-3 gr/24 hrs were associated with a 
preeclampsia recurrence risk of 12% and almost twice as high (22%) when proteinuria levels 
were ≥ 3 g/24 hrs in the index pregnancy. (192)   
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 In summary, the relationship between previous history of preeclampsia and recurrence of 
the disease is well documented. Having had preeclampsia in a previous pregnancy increases the 
likelihood that a subsequent pregnancy will also be affected by preeclampsia. 
2.4.4. Age 
Young age (under 20) has frequently been reported as risk factor for preeclampsia.(155) This 
finding has not been replicated in all studies. It is possible that the observed age-associated risk 
is due to the fact that younger women are more likely to be primiparous, and therefore parity 
may be the underlying mechanism that places younger women at risk for preeclampsia. 
However, a nested case control study by Mittendorf et al, revealed no association between young 
maternal age (less than 19) and preeclampsia.(125) Furthermore, several population studies that 
adjusted for parity did not indicate that younger women were at a greater risk of preeclampsia.(76) 
(160)
There seems to be consistent evidence, however, that older women (over 35) are at 
increased risk of preeclampsia. (149) In the same study mentioned above, Mittendorf, et al found 
that women older than 34 were at increased risk of preeclampsia (OR 2.5, CI 1.8-3.5) in 
univariate analysis, but after adjusting for parity, no independent effect of advanced maternal age 
was observed. In a review of the literature on older maternal age and pregnancy outcome, 
Hansen JP found that in comparison to younger women, older women were two to four times 
more likely to develop preeclampsia.(73) Similarly, in a Finnish population study, Hartikainen A-
L et al showed that women older than 35 were at higher risk (OR 2.5, 95% CI 1.5-4.1). (76)  
Despite many reports linking advanced maternal age with increased risk of preeclampsia, it 
is difficult to determine with certainty whether older women are indeed at greater risk compared 
to younger women. Some studies have not adjusted for parity and those that have, found parity 
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 and other factors such as multiple pregnancies confounded the relationship between age and 
preeclampsia. In addition, Chesley suggested that the association between older maternal age and 
preeclampsia is likely due to the tendency of older women to have essential hypertension. (32) It 
is possible that the observed association between advanced maternal age and preeclampsia may 
be due to the higher frequency of multiple pregnancies in older mothers, which places older 
mothers at greater risk.  
2.4.5. Race 
Many studies indicate that race is associated with increased risk of preeclampsia. (130) For 
example, Eskenazi et al,(55) in multivariate analyses of preeclampsia risk factors showed that 
black race was a significant risk factor for preeclampsia but only in nulliparous women (adjusted 
OR 12.3, 95% CI 1.6-100.8). In 1992, Savitz, in a study of pregnancy outcomes derived from 
North Carolina’s 1988-1989 vital statistics data, found similar preeclampsia incidence in both 
black and white women. (159)    
Interestingly, traditional preeclampsia risk factors vary across ethnic groups. For 
example, Knuist, et al (1998), in a prospective investigation of preeclampsia predictors found 
that unlike in white women, increase in diastolic blood pressure did not predict preeclampsia in 
black women, but increased maternal age was more likely to be a predictor among blacks. The 
observed race-associated relationship may be attributed to the tendency of black women to also 
suffer from chronic hypertension, and obesity. (94)  
In summary, the available epidemiologic evidence suggesting black race as risk factor for 
preeclampsia is currently unclear. Many studies suggest that black women are twice more likely 
to develop preeclampsia compared to white women. However, it should be noted that many of 
 23
 these studies did not consistently account for potential confounders including sociodemographic 
factors, obesity and chronic hypertension. 
2.4.6. Family History 
Several lines of evidence suggest that preeclampsia may be an inheritable disorder, but the exact 
inheritance pattern has not yet been found. (7)
For example, Chesley and colleagues reported a 26% incidence of preeclampsia in daughters of 
women with preeclampsia, but only 8% incidence in the daughter-in-law. (31) Similarly, data 
from a pregnancy cohort in Scotland that had been followed for several decades found that 
preeclampsia was more likely to occur in sisters (2.5- to 3.4-fold), mothers (4-fold), and mothers-
in-law (4.4%) of women who have had preeclampsia, compared to mothers of controls 
(3.5%).(182)
These findings were replicated in a prospective investigation of 368 primigravid women. 
Eighteen women (18/368) reported having a mother and, or sister who developed preeclampsia. 
Of this eighteen, 27.8% (5/18) developed preeclampsia compared to only 8.3% (29/350) with no 
family history of preeclampsia (RR 3.4, 95% CI 1.5-7.6).(34) In addition, family history was 
associated with severity of preeclampsia. For example, among women who had a family history 
of preeclampsia, 22.2% (4/368) developed severe preeclampsia, compared to 5.1% (18/350) with 
no history of preeclampsia (RR 4.3, 95% CI 1.6-11.5). (34)(47)
Similarly, Arngrimsson et al studied the genetic and familial predisposition to 
preeclampsia in a defined population in Iceland. In this study, inheritance patterns in four-
generation families were followed through both sons and daughters. Authors were not able to 
differentiate between autosomal recessive and autosomal dominant inheritance. (7)  
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 According to a population-based study of approximately 1.7 million births in Norway, 
(108) a man who has fathered a child in a previous preeclamptic pregnancy is twice as likely to 
father a preeclamptic pregnancy with a different woman. Interestingly, men whose mothers had 
preeclampsia while pregnant with them are twice as likely to father a child who is the product of 
a preeclamptic pregnancy.  This suggests a genetic predisposition to preeclampsia that can be 
transmitted both maternally and paternally.  
  An additional approach employed in determining a potential genetic influence on 
preeclampsia has been the study of frequency of preeclampsia in different twin zygosity groups, 
but so far findings have been inconclusive. In two studies of monozygotic twins, none of 10 twin 
pairs were found to be concordant for preeclampsia. (185)(184)  
In summary, a familial predisposition to preeclampsia has been documented in many 
studies, suggesting that genetic factors aid in the development of this disorder. However, the 
study of a genetic predisposition to preeclampsia is hindered by the multi-systemic nature of the 
disease. For example, there is currently no single agreed upon preeclampsia phenotype. 
Furthermore, preeclampsia is a pregnancy specific disorder and therefore any potential 
preeclampsia allele is limited to pregnant women. Considering that delivery of the fetus is the 
only effective cure for this disorder, expression of a preeclampsia gene may be interrupted in the 
process. (198)
2.4.7. Chronic Hypertension 
Eskanazi (1991), reported in a case control study that preeclampsia was twice more likely to 
occur in women with a previous history of hypertension.(55) In another study, Rey and 
Couturier,(147) found that women with chronic hypertension were ten times more likely to 
develop preeclampsia than normotensive women. Furthermore, perinatal deaths were more 
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 common in women who had chronic hypertension with superimposed preeclampsia (101/1000) 
compared to controls (12/1000). (147) Page and Christianson prospectively followed a cohort of 
black (N= 2880) and white women (N=10,074) and divided them into four groups: 1) with 
chronic hypertension; 2) without chronic hypertension; 3) with superimposed preeclampsia; and 
4) without superimposed preeclampsia. Perinatal deaths among women with chronic 
hypertension were 2-to 3-fold higher compared to normotensives without proteinuria and ten 
times higher among women with chronic hypertension and superimposed preeclampsia. (135)
In summary, women with chronic hypertension are at substantial risk of developing 
preeclampsia. 
2.4.8. Body Mass Index (BMI) 
Several epidemiologic studies indicate that increased maternal adiposity, as measured by high 
body mass index (BMI) significantly increases the risk of preeclampsia (three- to six-fold 
increase).(55) Sibai and colleagues, in a large multi-center trial studying the effect of calcium 
supplementation on the incidence of preeclampsia, found that women with BMI greater than 34 
kg/m2 early in the second trimester had the highest incidence of preeclampsia (12.6%).(169) 
Nulliparous women with this level of BMI were at a 4.9 fold increased risk of preeclampsia, 
whereas multiparous women were at 5.1-fold increased risk.(181) This association remained 
significant after adjusting for race, prior history of preeclampsia and clinic service (OR 3.5, 95% 
CI 1.7-7.5).  
In a case control study conducted by Mittendorf and colleagues (125), heavy women (BMI 
> 30) were at increased risk for preeclampsia (Adjusted OR 2.7, 95% CI 1.6-4.4). Additionally, 
in a population-based study of 96,801 primiparous women who delivered singleton births in 
Washington State between 1992-1996, both obese women (BMI ≥ 30) (OR 3.3, 95% CI 3.0-3.7) 
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 and women who were overweight before pregnancy (BMI 25-29) were more likely to develop 
preeclampsia (OR 2.0, 95% CI 1.8-2.52). (51) In a prospective multicenter study of aspirin use for 
the prevention of preeclampsia, Sibai and colleagues demonstrated an independent dose-response 
relationship between relative weight and incidence of preeclampsia in primiparous women. (167)  
In summary, evidence from several well-controlled studies indicates that obesity is a 
significant risk factor for preeclampsia. 
2.4.9. Protein Intake 
World War I and World War II brought an explosion of reports describing a potential 
relationship between protein intake and preeclampsia. It was widely speculated that the disease 
was the result of high intakes of protein, and that evidence for this could be found in the 
decreased incidence of preeclampsia attributed to food shortages during war years. Chesley 
questioned the reliability of these findings. He suggested that the observed decline in 
preeclampsia was more likely due to a decline in primiparous births during the war. Most males 
remaining at home during this time had large families, and had wives who had pregnancies as 
multiparas. (31) In addition, many studies did not control for the possible association between 
protein intake and maternal socio-demographic factors. For example, protein intakes are often 
associated with socioeconomic factors such as poverty, poor eating and health habits. 
Furthermore, the exact processes involved in dietary protein break down and synthesis and their 
potential influence on blood pressure regulation is currently not known.  
In summary, due to poor study design and a lack of understanding of the biochemical 
mechanism underlying the effect of dietary protein metabolism on blood pressure regulation, no 
firm conclusions on the link between dietary protein and blood pressure can as yet be made. (134)     
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 2.4.10. Diabetes 
Diabetes is also a risk factor for preeclampsia. The exact mechanism driving this relationship is 
not known, but obesity and insulin resistance may be predisposing factors. For example, several 
lines of evidence suggest an association between obesity, type-2 diabetes, insulin resistance, and 
hypertension. (143)(144)(111)(126)(122) Among 140 nulliparous black women with known fasting 
glucose and insulin, Sowers et al found fasting insulin levels to be 1.8-fold higher in 
preeclamptics compared to normotensives.  
 Garner et al, in a prospective study of 334 pregnant diabetic women, reported a 
preeclampsia incidence of 10% among diabetics compared to 4% in controls. (66) Furthermore, 
the rate of preelampsia among diabetics was elevated with increasing severity and duration of 
diabetes, from 9% among diet-controlled gestational diabetes to 30% among women with White 
classes D, F, and R. (66)(129)
In summary, women with pregestational diabetes are twice more likely to develop 
preeclampsia compared to women with gestational diabetes. 
2.4.11.   Cigarette Smoking 
 
Smoking has consistently been associated with a reduced risk of preeclampsia, even after 
cessation of smoking. At present, the exact mechanism underlying this association is not known, 
but suggestions made in the past attribute this protective effect to decreased expansion of plasma 
volume among smokers, (114) hypotensive effects of toxic byproducts (thiocyanate) of smoking, 
and to vasoconstriction and platelet aggregation resulting from nicotine-induced inhibition of 
thromboxane production. (93)(204)
Cnattingius et al, in a population-based study of 317,652 nulliparous women aged 15 to 34 
years who delivered singleton pregnancies in Sweden from 1987 through 1993, found that 
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 maternal smoking was associated with significantly reduced risks of mild and severe 
preeclampsia (RR=0.6 and 0.5, respectively). However, smoking at least 10 cigarettes per day 
was associated with increased rates of perinatal mortality (from 24 to 36 per 1000), abruption 
placentae (from 31 to 67 per 1000), and small for gestational age (from 28% to 68%). (37)  
A dose response relationship was reported in a prospective study that used data from the 
Collaborative Perinatal Project. After controlling for prepregnancy body mass, age, 
socioeconomic status, and race, both past smoking and smoking during pregnancy was 
associated in a dose response pattern with reduced risks of gestational hypertension and 
preeclampsia. For example, among women who smoked ≥ 10 cigarettes/day, the relative risk of 
preeclampsia was 0.5 (95% CI 0.4-0.7) in comparison to nonsmokers. (206)
Similar findings were observed in another population-based study comprising the National 
Birth Registry of Sweden in 1993 and data collected from 1990 to 1994 at the Malmo University 
Hospital. Multivariate regression analysis for the University-based study showed that, in 
comparison to non-smokers, moderate smokers (1-9 cigarettes per day) had a lower incidence of 
preeclampsia (OR 0.4, 95% CI 0.2-0.6). This finding was replicated in the National series, in 
which preeclampsia incidence was also significantly lower for moderate smokers (OR 0.6, 95% 
0.5-0.7). (109)
In summary, the evidence suggesting a reduced risk of preeclampsia associated with 
smoking has been consistent. This protective effect remains even after cessation of smoking. 
Further research is needed to reveal the mechanism for the smoking effect. 
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 2.4.12.   Prevention Studies 
Preeclampsia prevention studies are hindered by the lack of knowledge of the precise 
pathohysiologic mechanisms underlying this disorder. Therefore, prevention strategies may not 
alter development of disease, but merely treat its symptoms. Another limitation is over-reliance 
on lowering of high blood pressure as a target of prevention. In preeclampsia, elevation of blood 
pressure tends to occur at a later stage in pregnancy in comparison to other serious early-onset 
symptoms. Therefore, elevation in blood pressure, by itself, may not be a sensitive marker for the 
underlying pathophysiology observed in preeclamptic pregnancies. In the past, because of over-
reliance on second trimester blood pressure elevations as indicator of preeclampsia, a large 
number of studies have mistakenly classified gestational hypertension as preeclampsia. 
 Ideally, in order to predict who will develop preeclampsia, factors involved in the 
disease process should be identified prior to onset of disease, and should be biologically 
plausible. This increases the likelihood that treatment strategies will target risk factors that 
actually matter in the disease process. Moreover, preeclampsia affects but 3% of the population, 
which means that even if an effective treatment becomes available, the potential exists that a 
large number of the obstetrical population will be treated unnecessarily. Nevertheless, one could 
argue that preeclampsia sequelae are sufficiently serious to warrant a search for effective 
treatment strategies.  
Numerous controlled studies targeted oral calcium supplementation as a potential 
preventive strategy. The rationale for using calcium is based on calcium’s potential for lowering 
blood pressure. A few studies found significant reductions in preeclampsia incidence, but others 
reported no change. In a meta-analysis of randomized controlled trials, calcium supplementation 
was found to be highly effective in preventing preeclampsia (OR 0.38, 95% CI 0.22-0.65).(25) 
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 This study showed a statistically significant 1.68 mmHg decrease in systolic blood pressure 
among hypertensive women supplemented with 1 g of calcium per day. These results were not 
replicated, however, in a subsequent large double-masked trial (RR 0.94, 95% CI 0.76-1.16) (107) 
and six other double-masked studies. Authors of the meta-analysis questioned the clinical 
significance of a 2 mmHg reduction in systolic blood pressure in the absence of a reduction in 
diastolic pressure, and went on to recommend calcium supplementation only for women who 
would benefit the most from supplementation, such as women with osteoporosis. 
Aspirin has long been suggested as another approach to treating preeclampsia. A number 
of early clinical trials and meta-analyses have suggested that low dose aspirin is effective in 
preventing preeclampsia. The rationale for this suggestion is based on the observation that 
preeclampsia was found to be associated with disturbances in prostanoid and platelet function, 
(14)(197)(160)(15)(115)(188)(78)(46)(36) and that aspirin may be effective in decreasing platelet thromboxane 
synthesis while maintaining vascular wall prostacyclin synthesis. (46)(35)(137) For example, Sibai et 
al, in a randomized multicenter study of 3,135 nulliparous women, found that preeclampsia 
incidence was 26% lower in women who received 60 mg aspirin daily compared to placebo 
group (RR 0.7, 95% CI 0.6-1.0). (167) In a multicenter study conducted in England (Collaborative 
Low-dose Aspirin Study in Pregnancy (CLASP)) (N=6,927), the use of aspirin (60 mg daily) 
was associated with a reduction of 12% preeclampsia incidence. These findings were 
contradicted by several subsequent randomized trials, which suggested that low dose aspirin had 
little effect on preeclampsia incidence. (68)(152)  
The Jamaica Low-dose Aspirin Study Group, found no differences in preeclampsia 
incidence between primiparous women (N= 6,275) randomized to 60 mg daily of low-dose 
aspirin and those on placebo (OR 1.15, 95% CI 0.92-1.44) (68). Similarly, Rotchell et al, in a 
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 randomized trial of 3,647 women to 75 mg controlled-released aspirin or placebo, found no 
difference between treatment and placebo groups (2.2% in the treatment group and 2.5% in the 
placebo group developed preeclampsia.(152) One major criticism of these trials was their 
enrollment of low-risk women. Enrollment of a low risk population may have made it difficult to 
detect any effect of low-dose aspirin on preeclampsia incidence. In response to this criticism, the 
National Institute of Child Health and Development (NICHD) in 1998 sponsored a multicenter 
randomized trial of low-dose aspirin. (28)(132) In this trial, high-risk preeclamptics including 471 
women with pre-gestational insulin-treated diabetes mellitus, 774 women with chronic 
hypertension, 688 women with multifetal pregnancies, and 606 women with a history of 
preeclampsia during a previous pregnancy, were randomized to 60 mg low-dose aspirin daily or 
placebo. Results showed no beneficial effect of low-dose aspirin in any of the preeclampsia high-
risk subgroups. 
In summary, evidence from large clinical trials, so far, do not indicate that routine 
calcium or aspirin supplementation reduce the incidence of hypertension. 
 
2.5.   EPIDEMIOLOGY OF HERPES SIMPLEX VIRUSES 
2.5.1. Herpes Simplex Types 1 and 2 
HSV-1 and 2 are members of the alpha Herpesviridae family of viruses. HSV-1 infects the 
oropharynx, and is usually not transmitted by genital contact. (128)(41)(118) It is estimated that 90% 
of people worldwide are seropositive for HSV-1 by the fourth decade of life, especially those of 
lower socioeconomic groups. (40) For example, seroprevalence surveys of western populations in 
the post-World War II era found that 80 to 100 percent of middle-aged adults of lower 
socioeconomic status were seropositive for HSV-1, as compared to 30 to 50 percent of adults of 
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 higher socioeconomic groups.(41) However, there has been an overall decline in HSV-1 
seroprevalence in industrialized countries in recent years. For example, 40 to 63% of people are 
now found to be seropositive for HSV-1. (40) It is unclear, whether the declining rates are due to 
changes in hygiene or to a protective effect imparted by previous infection with HSV-2. In a 
prospective study by Langenberg et al, approximately two-thirds of new HSV-1 infections were 
symptomatic and genital infections due to HSV-1 were as common as oropharyngeal infections 
(0.5 cases per 100-person years).(105) In the United States, over 600,000 new cases of herpes 
infection are anticipated every year .(202)
In contrast to the HSV-1 declining rates, seroprevalence surveys indicate that HSV-2 
infections have been increasing rapidly over the past several decades. US population-based 
surveys indicate that HSV-2 seroprevalence has increased from 16.4% (89) between 1976 and 
1980 to 21.7% (60) between 1988 and 1994. Furthermore, HSV-2 prevalence varies considerably 
depending on the population studied. For example, among STD clinic patients, HSV-2 
seroprevalence ranges from 8% to 83%, (128)(42)(77)(44)(41)(124) among prostitutes from 75% to 96%, 
(128)(41)(59) and in blood donors from 5% to 18%.(42)(60)(44)(41)(59) It is difficult to determine whether 
the observed increase in HSV-2 infections is due to actual increases in incidence or to 
improvement in diagnosis and treatment. Also, assessment of the extent of HSV-2 infection is 
made difficult because HSV-2 is not a reportable disease in most states. Furthermore, most 
people are asymptomatic and thus are unaware that they are infected.  
 One can differentiate between the two viral types based on the region of the body where 
they establish latency. HSV-1 normally resides in the trigeminal ganglion in the vicinity of the 
ear. HSV-2 establishes latency in the sacral ganglion at the base of the spine. Both viral types, 
however, are capable of straying away from their usual location. Symptoms of infections are less 
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 severe when the virus establishes latency away from its traditional site of residence. Severity of 
infection is also affected by the host immune system and duration of infection. A person is 
considered to have a primary HSV infection, if antibodies to HSV antigens were absent in an 
initial serum sample and were later found to be present in a subsequent sample. The symptoms of 
primary infections with HSV-1 and HSV-2 are similar, but a primary HSV-2 infection is usually 
more severe and reactivates with 16-fold greater frequency (Lafferty WE, et al 1987). Number of 
sexual partners, age of first sexual intercourse, and a history of other STDs are all consistent risk 
factors for HSV-2 infection. 
Serological studies are critical to the documentation of HSV infection because as many as 
75% of infected individuals acquire genital HSV-2 infection silently or have initial symptoms 
that are nonspecific. (20)
2.5.2. HSV Types 1 and 2 infection in pregnancy 
Between 6-50% of women attending antenatal clinics are seropositive for HSV-2 (Table 2). 
Although, neither HSV-1 nor HSV-2 poses major health threats, a first episode of genital herpes 
close to labor increases the risk of neonatal herpes. This is primarily because of a lack of HSV 
antibodies in maternal blood stream. Mothers with recurrent HSV infection have ample 
antibodies in their blood stream to protect the fetus, however, discerning a primary HSV 
infection from a recurrent one requires careful consideration. For example, in a study of 29 
pregnant women who were presumed to have primary HSV infection based on symptomatology 
alone, only 4 (14%) were found to actually have first episode disease as determined by type-
specific HSV serologic assay. (81) In addition, severity of infection may also be influenced by 
pre-existing immunity to HSV infections. For example, studies have shown that prior HSV-1 
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 infection may impart protection against HSV-2 acquisition. (24)(118)(177) Nonetheless, primary 
infection appears to have the greatest influence on adverse pregnancy outcomes.  
Several culture and serology studies have suggested an increased risk of adverse 
pregnancy outcomes, including spontaneous abortion, preterm birth, and intrauterine growth 
restriction in pregnancies complicated by primary genital herpes infection (21)(20)(128)(199)(202). For 
example, in a study conducted by Brown and colleagues at the University of Washington, 7,046 
patients susceptible to HSV infection showed that neonatal herpes occurred significantly more 
often among women with new serologic evidence of HSV infection at the time of labor (4 of 9) 
compared to those whose primary episode had concluded prior to labor (0 of 94) (p<0.001). (20) 
The incidence of neonatal herpes is influenced by the socioeconomic status, age and past sexual 
activity of the population studied.  
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 Table 2: HSV-2 Seroprevalence in Antenatal Clinic Attenders 
 
CITY NUMBER 
TESTED 
% POSITIVE TEST REFERENCE 
Tokyo 
Padua, Italy 
Seville, Spain 
Birmingham, Alabama (whites) 
Taiwan 
Sydney 
Stockholm 1969 
Lyon 
Rejkjavik, Iceland 
Stockholm 1983 
Stockholm 1989 
Stanford, USA 1991 
Atlanta (whites) 
Sao Paulo 1988-1989 
 (low and middle class) 
Seattle, USA 1990 
Sao Paulo 1988-1989 
 (very low income) 
Atlanta (blacks) 
Pittsburgh, PA 2002 
90 
NK 
NK 
NK 
NK 
229 
941 
NK 
NK 
1759 
1000 
277 
NK 
455 
 
201 
200 
 
NK 
200 
6 
8.4 
9.7 
11.4 
13.5 
14.5 
17 
17.3 
18.8 
32 
32 
32 
34.9 
36 
 
37.8 
42 
 
53.4 
25 
gG2 Immunodot 
gG2 Immunodot 
gG2 Immunodot 
gG2 Immunodot 
gG2 Immunodot 
gG2 ELISA 
gG2 ELISA 
gG2 Immunodot 
gG2 Immunodot 
gG2 ELISA 
gG2 ELISA 
gG2 ELISA 
gG2 Immunodot 
ELISA and  
Western blot 
Western blot 
ELISA and 
Western blot 
gG2 immunodot 
gG2 ELISA 
Hashido M, et al (1990) 
Nahmias AL, et al (1990) 
Nahmias AL, et al (1990) 
Nahmias AL, et al (1990) 
Nahmias AL, et al (1990) 
Cunningham AL, et al (1993)
Forsgren M, et al (1994) 
Nahmias AL, et al (1990) 
Nahmias AL, et al (1990) 
Forsgren M, et al (1994) 
Forsgren M, et al (1994) 
Kulhanjian JA, et al (1992) 
Nahmias AL, et al (1990) 
Weinberg A, et al (1993) 
 
Brown ZA, et al (1995) 
Weinberg A, et al (1993) 
 
Nahmias AL, et al (1990) 
Unpublished 
 
NK= not known; ELISA = enzyme immunoassay; gG2 = glycoprotein G2 
 
 
 
2.5.3. Cytomegalovirus (CMV) 
CMV is a member of the beta herpes virus subfamily. CMV is common across geographic 
locations and socioeconomic groups (Table 3). In industrialized countries CMV infects 
approximately 50% of the adult population, and in underdeveloped countries an even greater 
proportion of the population (90%) are infected by age 2. (49) In the United States CMV infects 
between 50% and 85% of adults by age of 40.  Common risk factors include: 1) non-white 
population; 2) low income; 3) breast feeding; 4) group care of children; 5) crowded living 
conditions and 6) sexual activity. Several sources, including estimates from large studies of 
blood donors, hospital workers and pregnant women, suggest an overall incidence of CMV 
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 infection in adults at 1-2% per year. (176)(11)(10)(70)(179) Transmission of the virus generally requires 
close contact with infected persons excreting the virus in saliva, urine, or other bodily fluids. 
CMV can also be transmitted sexually, via breast milk and transplanted organs (CDC). 
2.5.4. CMV infection in pregnancy 
Cytomegalovirus (CMV) represents the leading cause of congenital viral infection in the US. 
CMV is one of the most serious causes of morbidity in newborns, and in many instances 
manifestation of illness does not become apparent until school age.  For example, studies in both 
Sweden and the US indicate that a large number of infants with congenital CMV infection go on 
to develop sensorineural hearing loss. (75)(84) It is estimated that in the US, the overall rate of 
congenital CMV infection is at 1% of live births, which amounts to about 40,000 new cases per 
year, (17) of whom approximately 10% are clinically apparent at birth. (64) Approximately 50% of 
infants with symptomatic and 15% of infants with asymptomatic congenital CMV infection will 
experience hearing loss. (64)
Throughout pregnancy, women can acquire either a primary or recurrent CMV infection. 
Primary infection can best be determined by seroconversion of IgG antibodies to CMV, ideally, 
with at least two serum samples during pregnancy. The presence of IgG and IgM antibodies to 
CMV in an initially seronegative serum sample is usually considered good evidence of a primary 
infection. However, the presence of antibodies may also be an indication of a prior infection. A 
recurrent infection is defined as the presence of IgG antibodies before conception. Primary 
infection can be transmitted by saliva, breast milk, cervical secretions at birth, sexual intercourse, 
and blood transfusion. In the US approximately 10% of women shed CMV at the time of 
delivery, rates as high as 40% have been reported in Taiwanese women. (165) Re-infection, 
however, usually does not have severe pathologic consequences. For instance, Adler et al (2) 
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 showed that seropositive women were 90% resistant to infection by contact with CMV-shedding 
children, and along the same lines, Fowler et al (64) found that prior infection reduced maternal 
fetal transmission from 25% to 1% of pregnancies. Interestingly, several studies suggest that the 
rate of congenital infection is directly related to the prevalence of maternal CMV infection. For 
example, in populations with high CMV prevalence among women of childbearing age, the rate 
of congenital CMV infection tends to be high as well (Table 3). These findings, suggest that 
presence of antibodies to CMV does not necessarily prevent maternal transmission of the virus to 
her fetus, but does seem to prevent the fetus from developing serious disease. Primary infection 
is more likely to have serious health consequences for the fetus. 
   
Table 3: Rates of Congenital CMV Infection In Various Populations In Relationship To    
Prevalence Of Maternal Seropositivity 
 
LOCATION PERCENTAGE 
MOTHERS 
SEROPOSITIVE 
PERCENTAGE 
CONGENITAL 
CMV INFECTION 
REFERENCE 
Aarhus-Viborg, Denmark 52 0.40 Andersen HK, et al, 1979 
Abidjan, Ivory Coast 100 1.40 Schopfer K, et al, 1978 
Birmingham, Alabama, 
USA 
          Low SES 
          Middle SES 
 
77 
36 
 
1.25 
0.53 
Stagno S, et al, 1986 
Hamilton, Ontario, 
Canada 
44 0.42 Larke RBP, et al, 1980 
London, UK 56 0.30 Peckham CS, et al, 1983 
São Paulo, Brazil 
          Low SES 
          Middle SES 
 
84 
67 
 
0.98 
0.46 
Pannuti CS, et al, 1985  
Seoul, South Korea 96 1.20 Sohn YM, et al, 1992 
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 2.5.5. Epstein Barr Virus (EBV) 
EBV is a member of the gamma herpes virus subfamily. EBV infection in humans usually occurs 
by exposure to saliva, mostly during childhood. Latent infection is established in lymphocytes. 
Unlike other herpes viruses, EBV causes no clinical manifestations in the vast majority of 
individuals. Once infected with EBV, a latent infection persists for life. In addition, the virus can 
be shed asymptomatically and thus easily spread from person to person through intimate contact, 
such as kissing, hence the expression “kissing disease.” (139) In industrialized countries almost 
everyone has become seropositive by the age of 25 to 30 years, whereas seroconversion occurs 
earlier in developing countries. (57) For example, in the US, 50% of the population demonstrates 
EBV antibodies before the age of 5 years, 90 to 95% by adulthood. (57) EBV initially infects 
epithelial cells in the oropharynx. The B cells in nearby lymphoid tissue are then infected, and 
virus disseminates throughout the lymphoreticular system. (139) Like other herpes virus 
infections, EBV infection can reactivate. During this period of reactivation the virus is shed from 
the oropharynx, and occasionally from the cervix. (127)(140)(172)(183) EBV has been recovered from 
genital mucosa of women with acute infectious mononucleosis, suggesting that the virus was 
disseminated from the oropharynx to distant mucosal sites or that infection was introduced 
through sexual contact. Consensus has yet to be reached on whether EBV infections can be 
transmitted sexually.  
EBV infection can cause a benign lymphoproliferative disease known as mononucleosis, 
(121) but is not known to cause pregnancy-associated complications such as miscarriage or birth 
defects. This may be due to the rare occurrence of primary infections in pregnancy, since most 
people are already immune by childhood. 
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 2.5.6. EBV infection in pregnancy 
 
Only 1.3 to 4.2% of pregnant women in industrialized countries lack EBV antibodies, which 
means that primary infections rarely occur during pregnancy. For example, in various serological 
studies seroconversion ranged from 0.06% to 1.96% in pregnant women. (121)(67)(61)(88). EBV 
infections are not normally known to cause adverse pregnancy outcomes, but an early report by 
Icart and Didier showed correlation between presence of EBV antibodies during pregnancy and 
fetal abnormalities, but these findings were not replicated in a subsequent investigation. (61) In a 
more recent serological study designed to investigate mother-to-child EBV transmission, EBV 
antibodies were detected in 6% of neonates (5/83). Unfortunately, no follow up was conducted to 
determine if neonates developed abnormalities.   
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3. PATHOGENESIS OF PREECLAMPSIA 
  
3.1.   CYTOTROPHOBLAST INVASION IN PREGNANCIES COMPLICATED BY 
PREECLAMPSIA 
Preeclampsia is a disorder of placentation. Implantation in human pregnancy differs from 
implantation in other mammals by the occurrence of a second physiologic invasion of the uterine 
wall. The first implantation occurs in the first 6 to 8 weeks of pregnancy followed by a much 
deeper cytotrophoblast invasion between the 11th and 16th week of gestation. The key 
pathological lesion in preeclampsia is the inability of cytotrophoblast to attain sufficient depth 
during the second invasion.  It has been postulated that humans need this deeper physiological 
invasion to accommodate a larger brain. (116)  
As can be seen in fig 1, preeclamptic cytotrophoblast invasion is shallow in comparison 
to normal pregnancy. Shallow invasion may result in poor vascular exchange between mother 
and fetus, frequently resulting in intrauterine growth restriction (IUGR) and perinatal 
mortality.(43) Furthermore, experimental studies have demonstrated the occurrence of incomplete 
modification of the uteroplacental spiral arteries by invading extravillous cytotrophoblast in the 
first and second trimesters of preeclamptic pregnancies.(194) Under normal circumstances, such as 
in normal pregnancy, spiral arteries are transformed from epithelial to endothelial phenotype. 
The invasion and modification of the maternal spiral arteries to create the uteroplacental arteries 
by extravillous cytotrophoblast with subsequent endothelial regeneration is a fundamental 
process in implantation. (91) This transformation does not occur in preeclampsia, causing vessels 
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 to remain thick-walled and muscular. (207) As a result of defective invasion of trophoblastic cells, 
the maternal spiral arterioles are not transformed into the high volume, low resistance 
capacitance vessels capable of supplying the placenta with maximal blood flow. (54) The result is 
a hypoperfused placenta and an imbalance in maternal blood supply. The mother tries to 
compensate by elevating her blood pressure in an attempt to save her fetus by increasing its 
delivery of oxygen and nutrients. When she is no longer able to cope with fetal demands, the 
placenta signals for help by triggering a series of events that leads up to onset of preeclampsia. 
One such event is believed to be the release of cytotoxic factors that in turn can damage maternal 
endothelium, however the exact chronology of events is not known.   
 
 
 
Figure 1: A Comparison Between Uninvaded Arteries (non-pregnant), Normal Pregnancy and Preeclampsia 
and IUGR 
Source: Ashley Moffett-King. Nature Reviews Immunology 2002;2:656-663 
Figure used with author’s permission 
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 3.2.   UP-REGULATION OF INFLAMMATION 
Preeclampsia is a multi-systemic disorder of human pregnancy complicating 2-4% of the 
obstetric population. Preeclampsia is characterized by new onset hypertension and proteinuria 
after 20th week of gestation in a previously normotensive woman, and is associated with preterm 
delivery, fetal growth restriction, and abruptio placentae. In the United States, from the years 
1979 to 1986, preeclampsia-eclampsia was the second leading cause of maternal death and ranks 
between the second and third leading cause of maternal death in more recent years. (155) The 
search for a causative agent and potential unifying pathophysiological mechanism has been 
ongoing for decades, but what seems to be consistent is the occurrence of endothelial 
dysfunction in almost all aspects of the disease. In 1989, Roberts et al postulated that the clinical 
manifestations of preeclampsia, including hypertension, oxidative stress, and proteinuria could 
be explained by a generalized maternal endothelium dysfunction (150). Redman, et al extended 
this hypothesis further by proposing that inflammation provides the oxidative insult to the 
endothelium seen in preeclampsia (145).  
Endothelial cells line inside walls of blood vessels and are responsible for regulation of 
vascular tone and thrombosis. In preeclampsia serum, there is increased level of thromboxane-
A2 and platelet aggregation in endothelial cells, which may affect vascular tone by inducing an 
imbalance of vasoconstriction and vasodilation, leading to disruption of endothelial cell function 
(131). It is unclear, however, whether inflammation occurs before development of preeclampsia or 
is a consequence of the disease itself. Nevertheless, studies have tested the utility of white blood 
cell counts as indirect evidence of inflammation. Sacks et al found that normal third trimester 
pregnancy is characterized by activation of peripheral blood leukocytes, which is further 
increased in preeclampsia.(153) Similarly, Mellembakken et al found evidence of leukocyte 
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 activation in venous blood from antecubital and uterine veins during cesarean sections in 30 
women with preeclampsia (117).  
Although studies have demonstrated evidence for an inflammatory response both in 
normal and preeclamptic pregnancies, in preeclampsia inflammation seems excessive. For 
example, a number of studies have found increased levels of pro-inflammatory cytokines, such 
as TNF-α, interleukin 6 (Table 4) and soluble phospholipase A2, as well as activated clotting and 
complement pathways, at higher levels in preeclamptics than in normotensive pregnancies.  
 
 
Table 4: Studies Examining The Relationship Between Pro-inflammatory Cytokines and 
Pregnancy Outcome 
 
REFERENCE/YEAR NORMAL PREG 
CYTOKINE LEVELS 
(IN PG OR ML) 
PREECLAMPSIA 
CYTOKINE LEVELS 
(IN PG OR ML) 
TYPE OF STUDY 
 IL-6 TNF-
α 
N IL-6 TNF-α N  
1. Rinehart et al/1999* 0.327 -- 4 0.623 -- 6 Cross sectional 
2. Sanchez et al/2000* -- 694.8 179 -- 920.1 125 Case control 
3. Amory et al/2001 38,000 3,649 12 45,000 11,243 12 Case control 
4. Benyo et al/2001 7.52 0.79 8 8.98 0.80 8 Cross sectional 
5. Visser W et al/2002* -- 1.67 21 -- 29 21 Case control 
 
* Differences in cytokine levels between preeclamptic and control women were significant 
 
3.3.   LACK OF MATERNAL TOLERANCE TO PATERNAL/FETAL ANTIGENS 
Under normal circumstances, cell surface antigens called Human Leukocyte Antigens (HLA) do 
not recognize self-antigens as foreign, and thus do not mount an adverse immune response. But 
when confronted with paternally derived fetal antigens, the potential exists for rejection. Mother 
and fetus, each have unique cell surface antigens (HLA). Despite the immediate danger of 
maternal immunologic recognition, the fetus manages to evade immune-mediated destruction. It 
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 has been suggested, that the lack of HLA antigens on the syncytiotrophoblast and the presence of 
only the non-classic HLA-G antigen, (133) allows fetal trophoblast to avoid maternal immune 
recognition. Goldman-Wohl DS, et al found that the expression of HLA-G is reduced greatly in 
trophoblasts from spontaneous abortions and patients with preeclampsia, (69) in contrast to the 
high level of expression of HLA-G in trophoblasts from normal pregnancies. (29)
Several lines of evidence suggest that it is a lack of developed tolerance to paternal 
antigens that places a woman at risk for rejection of the pregnancy, manifested as preeclampsia. 
This concept is corroborated by epidemiological reports of higher risk of preeclampsia with 
excessive inflammation, the tendency for the disorder to occur more often among first 
pregnancies, with short duration of sexual cohabitation prior to conception, with change in 
sexual partner, and in women with a history of barrier contraceptive use. Primigravidity has 
consistently been demonstrated as the strongest risk factor for preeclampsia. A longer period of 
preconceptional sexual cohabitation with the father of the pregnancy is protective, (150) and a 
change of partner causes a woman’s risk to revert to nearly the same level as for nulliparity. (151) 
Confirmation for this idea came from a Dutch study of 392 hypertensive multiparous patients, 
where it was demonstrated that multiparous preeclamptics changed partners more often (22-
25%) compared to normotensive multiparous patients. A subsequent prospective study by Trupin 
et al showed that the incidence of preeclampsia between nulliparous (3.2%) and multiparous 
patients (3%) who changed partners was higher compared to that for nulliparous patients (1.9%) 
who did not change partners. (187) However, more recent work by Baso, et al and Skjaerven et al, 
demonstrated that it is not partner change but increased inter-pregnancy interval that elevates the 
risk for preeclampsia. (12)(173) Basso, et al, extended this finding to suggest that subfertility may 
be the pathophysiology underlying the prolonged inter-pregnancy interval associated with 
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 preeclampsia. Barrier contraceptive use has been linked to an elevation in risk for preeclampsia, 
but this has not been replicated in other, larger studies. (92)(123)
 
3.4.   MATERNAL INFECTIONS AS RISK FACTORS FOR PREECLAMPSIA 
Intolerance to paternal antigens is not the only explanation for the immunologic response 
observed in preeclamptic pregnancies. An overall upregulation of immune mediators with 
resultant oxidative stress and endothelial dysfunction is triggered by infection. (112)(145)(153)(154) 
Several epidemiological studies have linked both bacterial and viral infections to preeclampsia 
(Table 13). Sartelet et al, in a case control study, showed that malaria infection contracted during 
pregnancy was associated with preeclampsia (adjusted OR 3.3, 95% CI 1.1-9.5). (157)  
 Two further case control studies found that having urinary tract infections conferred 
significant 4-5 fold increased risks for preeclampsia. (86)(125) These findings were replicated in a 
prospective investigation, which showed that asymptomatic bacteriuria was more common 
among preeclamptics (19%) compared to normal pregnancies (3-6%). (85) In another prospective 
study, Herrera JA et al, demonstrated a 64.7% reduction of preeclampsia in women treated for 
vaginal/cervical infections such as BV, C. trachomatis, T. vaginalis and group B 
streptococcus.(83) Similarly, in a Norwegian study, Trogstad LIS, et al showed an increased risk 
of developing preeclampsia among women who were seronegative for, and therefore at risk of 
acquiring, HSV-2, CMV and EBV. (186) In a recently published case control study conducted by 
Heine, et al, women with elevated titers of IgG to C. pneumoniae were found to have a three fold 
increased risk of preeclampsia (OR 3.1, 95% CI 1.2-7.9). (80)  
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4. RESEARCH STUDY 
 
4.1.   SPECIFIC AIMS 
Preeclampsia is an unpredictable disease of human pregnancy and is responsible for considerable 
maternal and perinatal morbidity. The only effective cure is delivery of the fetus. There is 
evidence to suggest that endothelial injury and dysfunction are manifested early on in the disease 
process, and may be part of an excessive inflammatory response to pregnancy. We propose that 
maternal infections may be one trigger for such inflammatory activation. Infections may trigger 
the release of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and 
interleukin (IL)-6 into maternal circulation. The resulting inflammation may stimulate 
recruitment of neutrophils and monocytes and activation of macrophages that may lead to 
induction of vascular injury.  
The specific aims of this research are as follows: 
Aim Study I: To determine the relationship between maternal infections with Herpes Simplex 1 
and 2 (HSV-1 and HSV-2), Cytomegalovirus (CMV), and Epstein Barr (EBV) infections and the 
risk of preeclampsia. 
 Hypothesis 1: Women who lack IgG antibodies to HSV 1 / 2, CMV, or EBV in the beginning of 
pregnancy are at increased risk for developing preeclampsia, and women with elevated IgG 
antibodies to these viral infections early in pregnancy are less likely to develop preeclampsia. 
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 Hypothesis 2:  Women who acquire a primary HSV 1 / 2, CMV, or EBV infection during 
pregnancy are at increased risk of developing preeclampsia. 
 
Aim Study II: To conduct a meta-analytic review of studies that explored the association 
between maternal infection and the risk of preeclampsia, and to determine the strength of this 
association.  
Aim 1 Study III: To examine the relationship between Genital Warts (HPV), Genital Herpes 
(HSV-2), Chlamydia trachomatis, Gonorrhea and the risk of preeclampsia in a population-based 
cohort of reproductive age women.  
Aim 2 Study III: To investigate multiple factors affecting infection status and their relation to 
preeclampsia.  
Hypothesis 1: Women who have preeclampsia are more likely to report infections including 
Genital Warts, Genital Herpes, Chlamydia trachomatis and Gonorrhea in comparison to normal 
pregnancies. 
Hypothesis 2: Behavioral, sociodemographic, and clinical factors may interact with infection to 
trigger preeclampsia. 
 
4.2.   METHODS (I) 
4.2.1. Study design (I): Serological associations among HSV-1 and HSV-2, CMV, 
EBV infections and the risk of preeclampsia 
 
Study I was a 1:3 matched case control study nested within the ongoing Pregnancy Evaluation 
Preeclampsia Prevention (PEPP) study at Pittsburgh’s Magee-Womens Hospital. The ultimate 
goal of the PEPP study was to determine factors associated with preeclampsia and whether these 
factors could help improve prediction of the disease. Since the inception of PEPP in 1993 until 
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 February 2002, a total of 2,892 pregnant women have been recruited. Blood samples were 
obtained from pregnant women at initiation of prenatal visits to the Outpatient Clinic at Magee-
Womens Hospital. Magee-Womens hospital is the largest provider of obstetrical care in 
Allegheny County. Since Magee deliveries account for almost half of all live births in this 
county, this cohort was an excellent opportunity to study the relationship between maternal 
herpes virus infections and preeclampsia. In addition, PEPP’s infrastructure tackles preeclampsia 
research in a coordinated manner, incorporating environmental, clinical and behavioral aspects 
of this maternal syndrome.  
PEPP fulfilled our research needs as follows: 1) The continual expanding PEPP database 
with its extensive clinical, behavioral and epidemiologic data enabled the selection of the 
relevant nested case and control groups for the study, 2) PEPP throughout the years has built a 
repository of well documented interview, medical chart abstraction and laboratory outcomes data 
on risk factors for preeclampsia, and 3) PEPP employs standardized procedures to ensure 
adherence to study protocols and a balanced sample representative of the general population. 
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 MAGEE-WOMENS HOSPITAL
 
~ 7,000 deliveries/yr  
 
 
 
Source Sample Study I: 
Prenatal Exposure and 
Preeclampsia Prevention 
(PEPP) Project 
 
Longitudinal Cohort (N=2,211) 
Target Sample: Study I 
 
? 51 Women with Preeclampsia 
? 150 Women with normal 
pregnancies 
?
?  
 
Figure 1: Study I Flow Diagram Private Physician
Practices 
 
N = 4200 (60%) 
 
 
 
Private Physician
Practices 
 
N = 2800 (40%) Excluded 
3 Cases 
2 Controls Final Sample Study I 
 
 48 Women with 
Preeclampsia 
 148 Women with normal
pregnancies Total Serum Samples Study I 
 
? 96 Case Sera 
? 296 Control Sera 
 4.2.2. Study Outcomes (I) 
 
The main outcome in Study I was maternal HSV 1 / 2, CMV and EBV viral seroconversions. 
4.2.3. Overall Eligibility Criteria (I) 
 
A sample of healthy primigravida women between 16 and 44 years of age at 22 weeks or less of 
gestation were identified from PEPP’s records and targeted for inclusion in the current study. 
Participants were originally identified at their first prenatal visit to the Outpatient Clinic at 
Magee-Womens Hospital. Consent was obtained from all eligible participants (Table 5) when 
they originally enrolled in the PEPP study, a brief baseline interview was conducted, and 
longitudinal blood samples taken as aliquots at the time they presented for prenatal care. For 
each preeclamptic case, three normotensive controls were selected, matched on age, parity and 
race. From an available cohort of 2,211 women registered for outpatient prenatal care, 50 
preeclamptic cases and 150 normotensive controls were selected to represent a 1:3 case control 
design (Fig 2).  
Controls were randomly selected from the same cohort. The earliest available serum 
sample obtained was chosen as early trimester sample and the latest available pre-delivery 
sample was chosen as convalescent sample. Due to lack of blood samples on 2 cases and 10 
controls, a total of 96 cases and 280 control sera were retrieved from PEPP’s bio-repository and 
shipped to the University of Washington Virology Laboratory in Seattle for determination of 
antibodies to HSV 1 / 2, CMV and EBV. 
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 Table 5: Eligibility Criteria for Participants in the PEPP Study 
 
CASES CONTROLS 
A) Elevated blood pressure (at least two readings 
fulfilling criteria) which returns to normal by 
12 weeks postpartum 
a. ≥30 mmHg change in SBP or ≥15 
mmHg in DBP from baseline* OR 
b. SBP ≥140 mmHg or DBP ≥90 mmHg 
if no baseline measurement 
B) Urinary protein 
      a.   Dipstick of random urine with 
            ≥2+ on voided or ≥1+ on 
           catheterized random specimen 
b. ≥0.5 g of protein in a 24 hour 
     urine collection 
C) Hyperuricemia (≥ 1 S.D above the 
        mean for gestational age) 
 
     A)   Blood pressure 
             a.    < 30 mmHg change in SBP and < 15 
                   mmHg in DBP from baseline and 
        
 
 
      
     B)   Urinary protein 
             a.   All dipsticks of random urines with 
                   <2+ on voided and < 1+ on catheterized 
                   random specimens 
             b.  < 0.3 g of protein in all 24 hour urine 
                  collections 
 
      C)   Hyperuricemia 
 
 
* Baseline = average blood pressure prior to 20 weeks gestation.
     
4.2.4. Study Population (I) 
 
The longitudinal cohort consisted of pregnant women who met all PEPP eligibility criteria but 
have not yet delivered. Furthermore, longitudinal patients had no history of diabetes or 
hypertension and met ACOG criteria for preeclampsia. The present study restricted sample 
selection to the longitudinal cohort, for several reasons: 1) because PEPP’s case designation 
occurred after delivery, the potential for selection bias was significantly reduced. In addition, 
essential indicators of sexual behavior and other information on covariates were collected prior 
to determining cases and controls; 2) with the longitudinal cohort it was possible to capture 
women initiating prenatal care prior to 22 weeks gestation, thereby allowing viral seroconversion 
to be defined more precisely. In addition, a longer follow up allowed for collection of more 
complete clinical and specimen data. 
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      Cases: Cases were selected from PEPP’s longitudinal cohort, and entailed a diagnosis  
 
of gestational hypertension with proteinuria. Additional criteria for case selection required that 
final designation of preeclampsia be made 12 weeks postpartum, after blood pressure and 
proteinuria returned to baseline levels. Diagnosis of preeclampsia in both PEPP and the current 
study represents a modified version of the definition proposed by the American College of 
Obstetrics and Gynecology. The rationale for adopting a modified version was to minimize the 
likelihood of classifying transient hypertension during pregnancy as preeclampsia. Gestational 
hypertension was defined as an increase of 30 mmHg in systolic blood pressure or 15 mmHg in 
diastolic blood pressure compared with values obtained before 20 weeks of gestation or as 
having an absolute blood pressure ≥ 140/90 mmHg that developed after 20 weeks of gestation if 
first trimester blood pressures were not known. Proteinuria was defined as > 500 mg per 24-hour 
urine collection or ≥ 2+ (100 mg/dL) on a voided or ≥1+ (30 mg/dL) on a catheterized random 
urine specimen.
 
     The following eligibility criteria were applied to cases: 1) primiparity, 2) single gestation, 3) 
no history of diabetes, 4) no history of cardiovascular disease, and 5) no history of hypertension. 
Multiparous women and women with twin pregnancies were excluded because the available 
epidemiologic evidence suggests fundamental differences in risk patterns associated with 
preeclampsia in these women. In particular, multiparous women who develop preeclampsia tend 
to have a history of prior preeclampsia and may be more likely to be at subclinical cardiovascular 
risk (J Roberts). Women with multiple gestations are excluded because their large placental size 
appears to place them at predictably higher risk for developing preeclampsia. Consequently, 
infection is less likely to be the cause of preeclampsia in such women. In addition, the 
substantially lower prevalence of preeclampsia in multiparous women and the substantially 
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 smaller number of women with multiple gestations would make it difficult to achieve adequate 
sample size in these subgroups (J Roberts). 
Controls: Controls consisted of pregnant women enrolled in the PEPP study who 
 did not experience preeclampsia. Three times as many controls were selected from the same 
longitudinal cohort and met the same inclusion criteria as cases: 1) primiparity, 2) singleton 
gestation, 3) no history of diabetes, 4) no history of cardiovascular disease, and 5) no history of 
hypertension. 
4.2.5. Data Collection (I) 
 
Data Management: A master file was created containing sera from cases and controls extracted 
from PEPP’s bio-specimen repository. This master file was divided into strata describing cases 
and controls by unique sample identification numbers and listed quantities available for the 
study. For each stratum, a serum aliquot was obtained from early and convalescent samples. 
After close scrutiny of records on this list, records missing the required 0.5 ml of maternal sera 
that was needed for the conduct of reliable viral serologies were excluded. Thus, the final study 
sample was comprised of 48 cases and 140 controls, with an overall total of 376 blood serum 
samples available for shipment. This excel file was then submitted to PEPP’s laboratory 
repository where the sera was pulled and packaged for shipment.  Sera was packaged according 
to this excel file in order to prevent mislabeling of vials. A second file, stripped of case control 
status and with the order of IDs rearranged, were included with the labeled and packaged sera 
and shipped to the virology laboratory at the University of Washington (Table 6). Results of 
serologic tests were recorded by laboratory personnel directly onto the second list (in an Excel 
spreadsheet). A third dataset was then created, by merging virology results to the baseline and 
clinical data file by sample record numbers. 
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Table 6: Example of blood serum master list containing the first two strata of the 1:3 case 
control study 
 
STRATA CC1 RECORD ID2 SAMPLE ID SAMPLE DATE SAMPLE TIME AMOUNT 
1 1       000112233      13579      12/23/99   
1 1       000112233      24687        8/15/00   
1 0       000456789      46810        7/25/99   
1 0       000456789      68103        2/18/00   
1 0       000678910      81012        1/20/00   
1 0       000678910      10125      10/18/00   
1 0       000345678      70012       4/15/00   
1 0       000345678      60034       8/12/00   
2 1       000891011      12146        2/18/01   
2 1       000891011      14168      10/20/01   
2 0       000910112      16182        1/17/01   
2 0       000910112      18204      10/12/01   
2 0       001011123      20226        4/10/01   
2 0       001011123      44246      12/05/01   
2 0       002456789      27289        3/10/01   
2 0       002456789      53435        5/06/01   
 
1 CC denotes case control status. For each stratum, a total of 2 (early and labor samples for the one case)case samples and  6 control 
samples (early and labor samples for the 3 controls) are listed 
2 Note that record numbers are identical for each pair, because each pair represents the same person, however, all sample ids are unique. 
Before samples are shipped to virology lab, the CC and RECORD ID columns will be deleted, and this modified list will be shipped 
packaged with the sera. Another copy of this modified list will be sent via e-mail to virology lab. 
 
Chart Reviews: An important data collection aspect in the present study was extraction of 
relevant information from PEPP’s database to be used in the case control analysis. The first step 
involved selection of cases and controls from PEPP’s longitudinal participant pool. Three 
controls were selected for each preeclampsia case and matched on age, parity and race. This was 
greatly facilitated by PEPP’s in-house diagnostic group who reviews and determines final 
assignment of cases on an ongoing basis. Additional queries of prenatal charts were conducted to 
obtain baseline primary risk factors, demographic information, medical history and information 
on social habits (Table 7). Additional variables were created from existing ones, such as interval 
period between early and convalescent samples, and length of cohabitation. The cohabitation 
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 variable was created by subtracting time of first sexual relations with partner from date of 
interview. 
 
Table 7: Data Collected on Study Population 
 
CATEGORY DATA COLLECTED 
1. Demographics Age, education completed, marital status, current 
employment status 
2. Behavioral Length of cohabitation with father of pregnancy 
3. Obstetric and gynecologic history Pregnancies 
4. Medical history Diabetes, hypertension, STDs 
5. Substance use Tobacco use, alcohol use, drug use 
6. Maternal anthropometric data Weight, height, BMI 
7. Medication use Oral contraceptive use, other contraceptives 
8. Laboratory data: viral serologies IgG antibodies to HSV-1, HSV-2, CMV, EBV 
 
 
Laboratory Data: Approximately 0.5 mL of blood sera from cases and controls were 
retrieved from -80ºC PEPP biospecimen storage at two time points (at 16-22 weeks gestation and 
at delivery), and shipped to the University of Washington virology laboratory for identification 
of serum antibodies to HSV-1, HSV-2, CMV and EBV. 
4.2.6. Methodological issues related to measurement of infection status (I) 
 
Detection of IgG Antibodies to HSV 1 / 2 Infections:  Accurate assessment of maternal 
exposures to infectious agents is highly dependent on the assumption that laboratory assessment 
of serology has high sensitivity and specificity. In the past, seroepidemiologic studies were 
unable to accurately distinguish between HSV-1 and HSV-2 infections due to cross-reactive 
antibodies between the two types. But with the introduction of glycoprotein gG enzyme-linked 
immunosorbent assay (ELISA), it is now possible to reliably determine whether someone has 
been infected with HSV-1, HSV-2 or both. HSV glycoprotein ELISA’s are now considered 
highly sensitive (>95%) and reproducible (coefficient of variation ≤ 5%). (82) The ELISA test 
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 used in the present study (HerpeSelect 1 and 2), has been tested against the Western blot test 
(gold standard) in a group of sera from 241 prenatal patients (9) and found to have sensitivity and 
specificity of 96% and 95% for HerpeSelect-1. The sensitivity and specificity for HerpeSelect-2 
were found to be 100% and 96%, respectively. 
Timing of Seroconversion: The timing of blood collection can limit the interpretation of 
HSV, CMV or EBV serologic results. A basic assumption in determining a subject’s serostatus is 
that change of infection status will occur only once, and hopefully this change will be captured in 
the time frame between collection of acute and convalescent samples. In some patients, antibody 
titers may fluctuate (rise and fall) significantly and in some instances fall to undetected levels 
within one month. Other patients may not develop significant antibodies at all. In these patients, 
misclassification of serostatus may be unavoidable. Preliminary data suggest that HSV-1 and 
HSV-2 antibodies can be detected a median of 2-3 weeks after the onset of first episodes of 
genital herpes.(9) Therefore, timing of blood specimen collection is of major importance, in 
determining seroconversion. It is possible that because of the shorter interval between acute and 
convalescent samples in preeclamptic subjects who deliver prematurely, as compared to 
normotensive subjects who do not, seroconversion may more likely be detected in normal sera. 
We addressed this potential problem by ensuring that time intervals between acute and 
convalescent sera were at least four weeks apart. In addition, we obtained gestational age 
adjusted risk measures of primary infection associated with preeclampsia. We also calculated 
time intervals between acute and convalescent samples to determine if sample intervals were 
significantly different for preeclamptics compared to normotensives. 
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 4.2.7. Serologic methods for antibody testing (I) 
 
HSV-1 and HSV-2: Maternal sera were tested using Enzyme-linked immunosorbent assay for the 
qualitative detection of human IgG class antibodies to HSV 1 / 2 (ELISA). The following 
procedures were followed for both HSV-1 and HSV-2: In the Focus Technologies HerpeSelect™ 
1 ELISA IgG assay, the polystyrene microwells were coated with recombinant gG-1 antigen. 
Diluted serum samples and controls were incubated in the wells to allow specific antibody 
present in the samples to react with the antigen. Nonspecific reactants were removed by washing 
and peroxidase-conjugated anti-human IgG was added and reacted with specific IgG. Excess 
conjugate was removed by washing. Enzyme substrate and chromogen were added, and the color 
allowed to develop. After adding the Stop Reagent, the resultant color change was quantified by 
a spectrophotometric reading of optical density (OD). Sample OD readings were compared with 
reference cut-off OD reading to determine results. (82) Results were reported as positive, negative 
or equivocal. A positive result entailed an index level of > 1.10 and was presumptive for the 
presence of IgG antibodies to HSV 1 / 2. A negative result entailed an index value of <0.90 
indicating no IgG antibodies to HSV 1 / 2 were detected. A result was equivocal if the index 
value was ≥ 0.90 but ≤ 1.10. As can be seen from Table 8 below, considering a 16% prevalence 
of HSV-1, and 25% for HSV-2 there is a high probability that a positive result with actually 
reflect actual disease (PPV). 
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 Table 8: Predictive Values of ELISA IgG Testing for HSV-1 and HSV-2 According to 
Prevalence of Infection in Expectant Mothers (82) 
 
PREVALENCE HSV-1 HSV-2 
 PPV(%) NPV(%) PPV(%) NPV(%) 
50% 95.2 95.2 96.2 96.1 
40% 93.0 96.7 94.5 97.4 
30% 89.6 97.9 91.7 98.3 
25% 87.0 98.3 89.5 98.7 
20% 83.3 98.8 86.5 99.0 
15% 77.9 99.1 81.9 99.3 
10% 69.0 99.4 74.0 99.6 
5% 51.3 99.7 57.4 99.8 
 
 
Serologic Methods for Antibody Testing of CMV: Detection of antibodies to CMV 
infection was made with ABBOTT CMV Total AB EIA immunoassay. This assay is a solid 
phase enzyme immunoassay for the qualitative detection of antibody to CMV in human serum or 
plasma as an indication of past or current infection with CMV. The following procedures were 
followed: Polystyrene beads coated with heat inactivated CMV antigen were incubated with 
diluted serum. Any antibody to CMV that is present is bound to the antigen on the solid phase. 
After aspiration of the unbound material and washing of the beads, anti-human immunoglobulin 
(containing antibodies against IgA, IgG, IgM, heavy and light chains) conjugated with 
horseradish peroxidase (HRPO) is allowed to react with the antigen-antibody complex on the 
beads. Unbound enzyme conjugate is then aspirated and the beads are washed. Next o-
Phenylenediamine (OPD) solution containing hydrogen peroxide is added to the beads and, after 
incubation, a yellow-orange color develops in proportion to the amount of antibody to CMV 
bound to the beads. The enzyme reaction is stopped by the addition of 1 N Sulfuric Acid. The 
absorbance of controls and specimens is determined using a spectrophotometer with the 
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 wavelength set at 492 nm. Specimens giving absorbance values equal to or greater than the 
cutoff are considered reactive for antibody to CMV. (1)
Serologic Methods for Antibody Testing of EBV: Antibodies to Epstein Barr Virus 
(EBV) was assessed by the Sigma Diagnostic EBV-VCA IgG ELISA test system. This is an 
enzyme-linked immunosorbent assay (ELISA) designed for the qualitative detection of IgG class 
antibodies to Epstein Barr Virus viral capsid antigen (EBV-VCA) in human serum. The test 
procedure involves three incubation steps: 1) diluted test sera are incubated in multi-wells coated 
with EBV-VCA antigen, and antigen specific antibody in the sample will bind to the 
immobilized antigen. The plate is washed to remove unbound antibody and other serum 
components, 2) peroxidase conjugated goat anti-human IgG is added to the wells and the plate is 
incubated. The conjugate will react with IgG antibody immobilized on the solid phase in step 1. 
The wells are washed to remove unreacted conjugate, 3) the multi-wells containing immobilized 
peroxidase conjugate are incubated with peroxidase substrate solution. Hydrolysis of the 
substrate by peroxidase produces a color change. After a period of time the reaction is stopped 
and the color intensity of the solution is measured photometrically. The color intensity of the 
solution depends upon the antibody concentration in the test sample. (170)
4.2.8. Data analysis strategy: Conditional logistic regression analysis (I) 
 
Virology results were coded without knowing case control status, and baseline infection status 
and seroconversion evaluated in relation to preeclampsia in matched analyses. Odds ratios and 
95% confidence intervals were estimated using conditional logistic regression with Stata 
statistical software (Stata Corporation, College Station, texas, version 7.0). A conditional 
analysis is appropriate in a 1:3 matched case control design, because it forms an exact likelihood 
function. Within each stratum, a likelihood function is formed based on an extensive listing of all 
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 possible combinations of cases and controls, conditional on the total number of cases and 
controls in the stratum (161). Only the discordant case control quartets regarding exposure were 
considered in analysis. Quartets where both cases and controls were positive or negative were 
excluded from analysis.  
The a priori hypotheses were that lack of baseline IgG antibodies and viral seroconversion 
denoted risks for preeclampsia, and persistent elevations in viral IgG antibodies conferred 
protection against preeclampsia. Categorical variables were created for each virus indicating 
seroconversion or no seroconversion (coded yes=1/no=0) and summarized as frequencies by case 
control status. Cases and controls were compared according to the following variables: marital 
status, smoking before and during pregnancy, BMI, income, length of cohabitation with partner, 
medical insurance, gestational age, and non-barrier and barrier contraceptive methods. In 
addition, because time interval between acute and convalescent samples are typically shorter for 
preeclamptics compared to normotensives, frequency of seroconversion was adjusted for sample 
interval time and Mantel-Haenszel procedure used to test for differences among groups.  
Continuous variables were summarized by means and standard deviations, and statistically 
significant differences determined by the Student’s t-test for variables that were normally 
distributed and the Wilcoxon test used for non-normally distributed continuous variables.  
Presence or absence of IgG antibodies to herpes viruses was determined based on criteria 
established by Enzyme-linked Immunosorbent Assay (ELISA) manufacturers. An index level of 
greater than 1.10 was considered positive. Descriptive statistics for IgG prevalence were 
calculated for the overall study population and separately for preeclamptics (cases) and 
normotensives (controls). Cross tabulations were obtained for each herpes virus variable 
(1=positive, 0=negative) by case control status, summarized by frequencies. The nature and 
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 relationship between continuous variables such as gestational age, smoking, sexual cohabitation, 
income, white blood cell count, platelet count and preeclampsia were assessed with scatter plots. 
Continuous variables will be summarized by means and standard deviations, and statistically 
significant differences determined by the Student’s t-test for variables that were normally 
distributed and the Wilcoxon test used for non-normally distributed continuous variables. Odds 
ratios and 95% confidence intervals were the primary test for strength of each association with 
preeclampsia. The a priori hypothesis was that lack of baseline IgG antibodies denoted risk of 
preeclampsia. 
  Primary infection was defined as viral seroconversion. A participant, who was HSV, 
CMV or EBV seronegative at baseline (first trimester) and her subsequent serum sample 
(labor/delivery) became positive, was considered to have seroconverted. Categorical variables 
were created for each virus indicating seroconversion or no seroconversion (yes=1/no=0) and 
summarized as frequencies. Cases and controls were compared according to the following 
variables: marital status, smoking during pregnancy, BMI, income, length of cohabitation, 
medical insurance, gestational age, birth control methods. Because time interval between acute 
and convalescent sample is typically shorter for preeclamptics compared to normotensives, 
frequency of seroconversion was estimated by time interval and Mantel-Haenszel procedure used 
to test for differences among groups. Baseline status and seroconversion were evaluated in 
relation to preeclampsia in matched analyses. 
Descriptive statistics for infection related variables were calculated for the study 
population as a whole and separately for cases and controls. In order to examine the impact of 
potential confounders on primary infections status, bivariate analyses using variables associated 
with case status and infection status were examined as stratification variables and summary 
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 statistics calculated using the Mantel-Haenszel method. (161) Conditional logistic regression 
models produced odds ratios for baseline serologic positivity or serconversion associated with 
preeclampsia, adjusting for the effects of other relevant parameters. All parameters that were 
significant at the level of p< 0.25 were entered into a subsequent conditional regression analysis. 
Next, parameters significant at the level of p < 0.10 were identified. A final logistic regression 
model was then fitted using a level of 0.05 as entry criteria. 
4.2.9. Sample size considerations (I) 
 
In order to determine the number of subjects required for the study, we considered the following: 
1) the prevalence of the disease in the general population, and 2) the prevalence (po) of the risk 
factor in the control population, and 3) establishment of the acceptable levels of Type I error and 
Type II error. Table 10 presents the number of subjects required to detect odds ratios of 1.5, 2.0, 
2.5, 3.0 and 3.5, with respect to primary infection.  
 
Table 9: Sample size needed to detect odds ratios of interest given various seroprevalence 
rates, case: control ratio of 1:3, two tailed α of 0.05 and β of 0.20. Numbers in the Table 
refer to the cumber of cases 
 
ODDS RATIO 0.20 0.25 0.30 0.35 0.40 0.45 
1.5 347 304 279 264 257 255 
2.0 109 98 92 88 88 89 
2.5 59 54 51 50 51 52 
3.0 40 37 35 35 36 37 
3.5 30 28 27 27 28 29 
 
The sample size listed is the number of subjects needed in the exposed group. Triple this number of subjects is 
needed in the unexposed group 
 
As can be seen in Table 9, assuming an overall prevalence of 30 to 50 percent exposure rate in 
controls and a 1 to 3 case control ratio, approximately 90 cases and 270 controls were needed to 
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 detect greater than twofold increase in risk with an α risk of 0.05 and a β risk of 0.20 (80% 
statistical power). 
4.2.10.   Potential problems (I) 
 
Confounding: We assessed the possibility that demographic, behavioral, and  
clinical parameters could impact the relationship between serology and preeclampsia. We were 
aware, however, that in any case control study unmeasured confounding may influence the 
observed associations. 
 Bias: Bias has been defined as “any systematic error in the design, conduct or analysis of 
a study that results in a mistaken estimate of an exposure’s effect on the risk of disease.” (161) 
Major types of biases in case control studies are, selection, misclassification and information 
biases. We accounted for selection bias by randomly selecting cases from a pregnancy cohort.  
 Misclassification bias occurs when patients are improperly assigned as cases or controls. 
This type of bias is a significant concern in preeclampsia studies due to a lack of gold standard in 
defining this disorder. Any misclassification would have the effect of biasing the observed 
association toward the null. Ideally, use of a rigorous case definition and juried case selection 
process may improve classification. We minimized the occurrence of this type of bias as follows: 
we expected that because preeclampsia is a relatively rare disease, controls were likely not have 
the disease. 
 Information bias was minimized because: 1) laboratory personnel were masked to case 
control status, and 2) women volunteered demographic and behavioral information prior to the 
occurrence of disease. 
 Data Validity: In order to ensure the reliability and validity of serologic measurements, 
sera were run in duplicate within the same assay. In addition, samples with different run dates 
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 were retested pair wise on the same ELISA plate and borderline serology results were retested as 
well. 
4.2.11.   Preeclampsia Diagnosis (I) 
 
Preeclampsia was diagnosed in accordance with guidelines proposed by the American College of 
Obstetrics and Gynecology (ACOG). Preeclampsia was defined as either a systolic blood 
pressure ≥ 140/90 mmHg or a diastolic level   ≥ 90 mmHg on repeated measurements that 
developed after 20 weeks of gestation. Proteinuria was defined as > 300 mg per 24-hour urine 
collection or ≥ 2+ (100 mg/dL) on a voided or ≥ 1+ (30 mg/dL) on a catheterized random urine 
specimen. Final designation of preeclampsia was made 12 weeks postpartum, after blood 
pressure and proteinuria returned to baseline levels.  
Covariates 
Medical history and other behavioral risk factors were obtained by abstraction of prenatal charts. 
We created an additional variable, interval time by calculating time period between early and 
convalescent sample blood draws. Information on covariates included gestational age, oral and 
barrier contraceptive use, education, smoking, BMI, income, sexual cohabitation with partner, 
and medical insurance.  
 
4.3.     RESULTS (I) 
Main characteristics of cases and controls are displayed in Tables 10 and 11. As can be seen, 
cases and controls did not differ significantly on gestational age, medical insurance, marital 
status, education, income, smoking, and contraceptive methods. However, a significant linear 
increase in preeclampsia was observed with increasing tertiles of BMI (p for trend = 0.03).  
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 Table 12 shows virology results by case control status and trimester of pregnancy. Among the 48 
cases, 23 (47.9%) lacked IgG antibodies to HSV 1 / 2, and 27 (56.3%) lacked IgG antibodies to 
CMV; among the 140 controls, 39 (27.9%) and 80 (57.1%) lacked antibodies to HSV 1 / 2 and 
CMV, respectively. Only 2 (4.2%) cases and 8 (5.7%) controls were EBV seronegative. We 
found that women who lacked antibodies to both HSV-1 and HSV-2 in early trimester were at 
significantly increased risk of developing preeclampsia (OR 2.9, 95% CI 1.3-6.4), whereas 
women who lacked antibodies to CMV (OR 0.9, 95% CI 0.4-1.9) and EBV (OR 0.7, 95% 0.2-
3.6) were not. In contrast, persistent elevations in IgG antibodies to HSV 1 / 2 appeared to lower 
the risk of preeclampsia (OR 0.5, 95% CI 0.2-1.0), whereas elevations in IgG antibodies to CMV 
was not associated with preeclampsia (OR 1.1, 95% CI 0.5-2.4).  
Five (10.4%) preeclamptics and four (2.9%) normotensives seroconverted for HSV 1 / 2 
or CMV. Seroconversion for HSV 1 / 2 or CMV was associated with a five-fold increased risk 
for developing preeclampsia (OR 5.4, 95% CI 1.0-29.0). This association remained significant 
after adjustment for education, income, smoking, years of cohabitation with partner, medical 
insurance, and type of birth control. There was no significant difference in early trimester and 
convalescent mean sample interval times between cases and controls, thus sample interval times 
did not affect risk estimates. The majority of women were seropositive for EBV (95.8 % of cases 
and 94.3% of controls) in the beginning of pregnancy. Hence we did not have sufficient power to 
determine the association between EBV primary infection and the risk of preeclampsia.   
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Table 10: Obstetric and Socio-demographic Characteristics of Preeclamptic Cases and 
Normotensive Controls (Paper I) 
 
Variable Preeclampsia  Cases (n=48) 
Normotensive 
Controls(n=140) 
Statistical 
Significance 
Gestational age (wks), mean  ± SD 
 
14.1 ± 10.4 14.3 ± 11.1 ns 
Gestational age (wks), mean ± SD at: 
    1st blood collection 
     2nd blood collection 
 
23.7 ± 14.3 
24.3 ± 14.6 
 
21.1 ± 14.5 
28.6 ± 14.7 
 
Sample interval time (wks), mean ± SD 
 
7.0 ± 1.0 7.0 ± 1.0 ns 
Medicare/Medicaid 
    No 
    Yes 
 
19 (39.6) 
29 (60.4) 
 
60 (42.9) 
80 (57.1) 
 
ns 
Marital Status 
    Never Married 
    Married 
 
22 (45.8) 
26 (54.2) 
 
61 (43.6) 
79 (56.4) 
 
ns 
Education 
    < High School 
    > High School 
 
29 (60.4) 
19 (39.6) 
 
69 (49.3) 
71 (50.7) 
 
ns 
Income 
    < 10K 
   10K-20K 
   20K-35K 
   35K-50K 
   50K-75K  
 
14 (29.2) 
5 (10.4) 
12 (25.0) 
11 (22.9) 
6 (12.5) 
 
33 (23.6) 
25 (17.9) 
22 (15.7) 
38 (27.1) 
22 (15.7) 
 
 
ns 
BMI 
   < 18 
  18-30 
   > 30 
 
28(62.2) 
   1(2.2) 
  16(35.6) 
 
105 (78.4) 
    2 (1.5) 
  27 (20.1) 
 
 
p = 0.03* 
 
Note: P values for gestational age were determined by use of t test, and for all other covariates by 
use of Chi-square test. * Test of trend determined with Mantel Haenszel Chi-square test 
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Table 11: Behavioral Characteristics and Contraceptive Method Use Among Preeclamptic 
Cases and Normotensive Controls (Paper I) 
 
Variable Preeclampsia  
Cases (n=48) 
Normotensive 
Controls(n=140) 
Statistical 
Significance 
Non-Barrier Birth Control 
Methods 
       No 
       Yes 
 
10 (20.8) 
38 (79.2) 
 
25 (17.9) 
115(82.1) 
 
ns 
Barrier Birth Control Methods 
       No 
       Yes 
 
25(52.1) 
23 (47.9) 
 
66 (47.1) 
74 (52.9) 
 
ns 
Smoked Before pregnancy 
cigarettes/day 
   1-9 
   10-19 
    > 20    
 
 
5 (11.6) 
5 (11.6) 
33 (76.7) 
 
 
19 (15.2) 
17 (13.6) 
89 (71.2) 
 
 
ns 
Smoked during pregnancy 
cigarettes/day  
   1-9 
   10-19 
    > 20    
 
 
  6 (23.1) 
  3 (11.5) 
17 (65.4) 
 
 
24 (23.5) 
  9 (8.8) 
69 (67.6) 
 
 
ns 
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Table 12: Risk of Preeclampsia Associated With Herpes Virus Infections (Paper I) 
 
Variable   Cases(a) Controls(a)   OR(e)     95% CI      
               (N = 48)  (N = 140) 
          ___________     __________  
         n (%)        n (%) 
 
Primary Infection(b)
Any (HSV 1 / 2, CMV)           5 (10.4)  4 (2.9)   5.4    (1.0-29.0) 
 
 
Lack of IgG Antibodies(c) 
    
HSV 1 / 2             23 (47.9)         39 (27.9)  2.9          (1.3-6.4) 
CMV              27 (56.3)         80 (57.1)            0.9          (0.4-1.9) 
EBV     2 (4.2)              8 (5.7)             0.7           (0.2-3.6) 
Elevated IgG Antibodies(d) 
 
HSV 1 / 2             19 (39.6)          78 (55.7)  0.5           (0.2-1.0) 
CMV              21 (43.8)          60 (42.9)           1.1           (0.2-1.0) 
EBV              46 (95.8)        132 (94.3)  1.4           (0.3-6.7) 
 
 
(a)  Cases and controls were matched for age, parity and race in all analyses 
(b)  Primary infection denotes participants who were seronegative at baseline and seropositive at delivery 
(c)  Lack of antibodies at baseline. Instances where both HSV-1 and HSV-2 were seronegative at baseline 
(d)  Patients with elevated IgG antibodies were seropositive (either HSV-1 or HSV-2) at baseline and remained 
seropositive at delivery 
(e)  Adjusted for smoking, BMI, Barrier (condom, spermicide, diaphragm, cervical cap, sponge) /Non-Barrier (oral 
contraceptive, Depo-Provera, withdrawal and no birth control method), gestational age, length of sexual 
cohabitation with partner, sample interval time 
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 4.4.   DISCUSSION (I) 
To our knowledge, the present investigation is the first study to show a significant association 
between newly acquired HSV-1, HSV-2 or CMV infections and preeclampsia. However, because 
of the relative small sample size involved in this study, a larger sufficiently powered prospective 
cohort study, designed to examine the association between maternal infection and preeclampsia 
is needed to confirm our initial observations. 
To date, eight epidemiologic studies have explored a potential association between 
maternal infections and preeclampsia. Sartelet et al, in a case control study, showed that malaria 
infection contracted during pregnancy was associated with preeclampsia (adjusted OR 3.3, 95% 
CI 1.1-9.5).(157) Two further case control studies found that having urinary tract infections 
conferred significant 4-5-fold increased risks for preeclampsia. (86)(125) These findings were 
replicated in a prospective investigation which showed that asymptomatic bacteriuria was more 
common among preeclamptics (19%) compared to normal pregnancies (3-6%). (85) In another 
prospective study, Herrera JA et al, demonstrated a 64.7% reduction of preeclampsia in women 
treated for vaginal/cervical infections such as BV, C. trachomatis, T. vaginalis, G. vaginalis and 
Group B streptococcus (83).  
In a Norwegian study, Trogstad LIS, et al showed an increased risk of developing 
preeclampsia among women who were seronegative for, and therefore at risk of acquiring, HSV-
2 (OR 1.7, 95% CI 0.7-4.2), CMV (OR 1.6, 95% CI 0.8-3.2) and EBV (OR 3.5, 95% CI 1.1-
10.6) infections.(186) Our results are consistent with Trogstad’s findings of an increased risk of 
preeclampsia associated with being seronegative for HSV-2 and CMV in the beginning of 
pregnancy. Unlike Trogstad, however, we found no association between preeclampsia and EBV 
seronegativity (OR 0.7, 95% CI 0.2-3.6). 
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 Another case control study conducted by Heine et al, women with elevated titers of IgG 
to C. pneumoniae were found to have a three-fold increased risk of preeclampsia (OR 3.1, 95% 
CI 1.2-7.9). (80) Similarly, in a recently published case control study, von Dadelszen et al, showed 
that women with early onset preeclampsia had higher levels of IgG to C. pneumoniae(0.354, 
95% CI 0.067-0.659) as compared to normotensives (0.207, 95% CI 0.105-0.359). They also 
demonstrated higher IgG levels to CMV (79, 95% CI 49-179) among preeclamptics compared to 
women with normal pregnancies (49, 95% CI 45-70). (194) Unlike von Daedelszen and 
colleagues, we found no association between CMV positivity and preeclampsia (OR 1.1, 95% CI 
0.2-1.0).    
A few potential study limitations merits mentioning. Case control studies are prone to a 
number of biases, primarily, misclassification, selection and information biases. 
Misclassification bias occurs when patients are improperly assigned as cases and controls. This 
type of bias is a significant concern in preeclampsia studies due to a lack of consistency in 
defining this disorder. The current study population consisted of a well-defined longitudinal 
pregnancy cohort with rigorous preeclampsia diagnostic criteria. In this study, case designation 
occurred after delivery. Thus misclassification of cases was unlikely. Also, essential indicators of 
sexual behavior and other information on covariates were collected prior to determining cases, 
and laboratory personnel were masked to case control status. Further, we excluded multiparous 
gravidas and twin gestation pregnancies because the available epidemiologic evidence suggests 
that these women are more likely to develop preeclampsia.  Consequently, infection is less likely 
to be the cause of preeclampsia in these women.  
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 Although we adjusted for major preeclampsia confounding factors, we cannot discount 
the possibility that unmeasured infection-related risk factors such as number of sexual partners 
may have confounded the relationship between infection and preeclampsia. 
Another potential source of bias was determination of infection status. Because the time 
interval between acute and convalescent samples may be shorter in preeclamptic subjects who 
may deliver prematurely, as compared to normotensives who do not, seroconversion may more 
likely be detected in normal sera. We addressed this problem by ensuring that time intervals 
between acute and convalescent sera were at least four weeks apart.  HSV-1 and HSV-2 
antibodies can be detected a median of 2-3 weeks after the onset of first episodes of genital 
herpes. (9) In addition, we obtained gestational age adjusted risk measures of primary infection 
associated with preeclampsia. We recognize, however, that in some patients levels of antibody 
titer may have varied and in some instances even declined to undetectable levels. In these 
patients, misclassification of serostatus is unavoidable.  
Between 6-50% of women attending prenatal clinics are seropositive for HSV-2, whereas a 
larger proportion, are seropositive for CMV and EBV. (64) Although infected individuals mount 
an antibody response, they continue to harbor these viruses, and can have recurrences. 
Nonetheless, primary infection appears to have the greatest influence on adverse pregnancy 
outcomes. (18)  
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 4.5
4.6
.   CONCLUSION (I) 
Our data suggest that primary infection with HSV, and possibly CMV may be associated with 
preeclampsia. Primary infections with these herpes viruses may contribute to the inflammatory 
burden of preeclamptic pregnancies. However, whether in utero viral infections may influence 
preeclampsia risk is not known. One possible implication of our finding is that women who are 
seronegative at the onset of pregnancy may benefit from preventive strategies that may not only 
reduce the incidence of preeclampsia but might also lower maternal morbidity and perinatal 
mortality associated with this maternal syndrome. 
 
.   METHODS (II) 
4.6.1. Study design (II): Association between maternal infection and preeclampsia: 
A systematic review of epidemiologic studies 
 
We searched MEDLINE, Cochrane, and Embase databases using a combination of search words: 
preeclampsia, preeclampsia and infection, maternal infection and hypertensive disorders.  
Inclusion criteria were: 1) study had to contain original data, 2) study design, 3) preeclampsia 
diagnosis, 4) techniques for detecting infection, and 5) adjustment for well-known preeclampsia 
confounders, including age, parity and multiple gestation pregnancies.  
In addition to obtaining information on the methodology used in the original studies, we 
abstracted the following information: 1) name of author/authors and year of publication, 2) 
number of subjects, and 3) strength of association (odds ratios) and 95% confidence intervals 
(see Table 13). Exposure was defined as presence or absence of infection. 
In the current meta-analysis, we required that studies utilize either the National High 
Blood Pressure Education Program (NHBPEP) criteria or the American College of Obstetrics 
and Gynecology (ACOG) criteria to define preeclampsia. Both define preeclampsia as a systolic 
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 blood pressure greater than 140 mmHg or a diastolic blood pressure greater than 90 mmHg 
accompanied by proteinuria of 300 mg/24 hr urine collection, or more than 2+ on a voided or 1+ 
on a cathetherized random urine specimen, in a previously normotensive woman. 
No institutional review board (IRB) approval was necessary, since only previously 
published data was used. All data was entered into Excel and later formatted as a STATA file in 
preparation for analysis.  
4.6.2. Statistical Analysis (II) 
 
The primary outcome was measure of association of bacterial or viral infections and the risk of 
preeclampsia compared to normotensive women. No adjustment for confounders was possible 
with the meta-analysis because only summary data was available. Individual study results were 
combined and heterogeneity between studies assessed with Q-statistics. (103) Based on a Q-
statistic p-value greater than 0.10, which indicated absence of heterogeneity between studies, a 
fixed effects model was used to calculate pooled odds ratios. The fixed effects model assumes 
that risk estimates are identical when studies are combined and that between-study variations are 
due to random errors. (103)
We considered the potential for publication bias by checking whether risk estimate 
differences between studies distorted results of the meta-analysis. This was accomplished by 
visually inspecting a funnel plot for asymmetry. A funnel plot graphically depicts the logarithm 
of the study odds ratios against their standard errors.(53)(180) All analyses were conducted with 
Stata™   7.0 (Stata™ Stata Corporation, 4905 Lakeway Drive, College Station, Texas 77845 
USA). Statistical significance was set at a probability level < 0.05. 
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 4.7.   RESULTS (II) 
4.7.1. Review of studies (II) 
 
Review of the literature yielded nine studies that have been conducted to date on the association 
between maternal infection and preeclampsia. Eight of these studies were published in peer-
reviewed journals between 1986 and 2004. We excluded one published study because no control 
group was specified. (83) Of the remaining seven studies, one was retrospective, (86) three were 
case controlled,(153)(125)(80) and another three were prospective.(85)(186)(194) With the exception of 
two studies (157)(186), the studies were conducted in the US. (85)(86)(125)(80)(194)  
Four studies explored whether maternal exposure to bacterial infections (asymptomatic 
bacteriuria, urinary tract infection, malaria, and C. pneumoniae) (157)(85)(83)(125) were associated 
with preeclampsia, and three examined this association with viral infections (HSV-2, CMV, and 
EBV).(186)(80)(194) We excluded one unpublished study, because exposure was defined differently 
from the studies included in the meta-analysis. Studies included in the meta-analysis used ACOG 
diagnostic criteria to define preeclampsia. The total combined population across the seven 
published studies was 1,382 preeclamptics and 4,555 normal pregnancies.  
Characteristics of studies included in this review are detailed in Table 13. Sartelet et al, in 
a case control study, showed that malaria infection contracted during pregnancy was associated 
with preeclampsia (adjusted OR 3.3, 95% CI 1.1-9.5).(157) Two further case control studies found 
that having urinary tract infections conferred significant 4-5-fold increased risks for 
preeclampsia.(83)(125) These findings were replicated in a prospective investigation which showed 
that asymptomatic bacteriuria was more common among preeclamptics (19%) compared to 
normal pregnancies (3-6%). (85)  
In a Norwegian study, Trogstad LIS, et al showed an increased risk of developing 
preeclampsia among women who were seronegative for, and therefore at risk of acquiring, HSV-
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 2 (OR 1.7, 95% CI 0.7-4.2), CMV (OR 1.6, 95% CI 0.8-3.2) and EBV (OR 3.5, 95% CI 1.1-
10.6) infections. (186)  
Another case control study conducted by Heine et al, women with elevated titers of IgG 
to C. pneumoniae were found to have a three-fold increased risk of preeclampsia (OR 3.1, 95% 
CI 1.2-7.9).(80) Similarly, in a recently published case control study, von Dadelszen et al, showed 
that women with early onset preeclampsia had higher levels of IgG to C. pneumoniae(0.354, 
95% CI 0.067-0.659) as compared to normotensives (0.207, 95% CI 0.105-0.359). They also 
demonstrated higher IgG levels to CMV (79, 95% CI 49-179) among preeclamptics compared to 
women with normal pregnancies (49, 95% CI 45-70). (194)  
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 Table 13: Characteristics of Studies Included in the Meta-analysis 
 AUTHOR/YEAR TYPE OF  
STUDY 
PREECLAMPSIA 
DIAGNOSIS 
INFECTIOUS  
AGENT STUDIED 
TECHNIQUE USED TO 
DEFINE INFECTION 
             N (%) OR (95% CI), %  
REDUCTION, 
INCIDENCE 
Sartelet et al/1996 Case control Maximum DBP of at
least 90 mmHg hrs 
preceding delivery 
Malaria  Histological obser- Ca: 17/32 (53.1) 
vation of infected  
red blood cells or  
Malaria pigment in  
macrophages or  
Fibrinoid (placenta) 
 
Co: 60/220 (27.3) 
 
3.3 (1.1-9.5) 
Hill et al/1986 Prospective ACOG criteria w/ asymptomatic  
bacteriuria 
w/o asymptomatic  
bacteriuria 
Presence of more 
than 100,000  
colonies of single  
bacterial species 
per 1 mL urine 
 
Ca: 19/100(19.0) 
Co: 3/100 (3.0) 
 
Preeclamptics:  
19% incidence 
Normotensives:  
3-6% incidence 
Hsu and Witter/1995 Retrospective  UTI Positive urine culture of 
> 100,000 bacteria  
Ca: 214/785(27.3) 
Co: 127/785(16.2) 
 
4.2 (1.05-5.09) 
Mittendorf R et al/1996 Case control ACOG criteria UTI Medical chart abstraction Cases: 386 
Controls: 2,355 
 
5.3 (2.9-9.7) 
Trogstad, et al/2001 Prospective   ACOG criteria 1)HSV-2
2)CMV 
3)EBV 
 
 
4)Toxoplasma  
    gondii 
1)HSV- IgG ELISA 
2)CMV-IgG ELISA 
3)EBV-antiEBV 
Recombinant EA  
IgG ELISA 
4)Platelia Toxo-IgG 
Ca: 6/33 (18.2), Co: 253/945(26.8)
Ca: 19/33(57.6), Co: 650/945(68.8)
Ca: 29/33(87.9), Co: 879/945(93.0)
Ca: 3/33(9.1), Co: 91/945(9.6) 
 
1.7 (0.7-4.2) 
1.6 (0.8-3.2) 
3.5 (1.1-10.6) 
1.0 (0.3-3.5) 
Heine RP, et al/2003 Case control ACOG criteria C. pneumoniae Microimmunofluorescenc
  
Ca: 25/37(67.6) 
Co: 15/37(40.5) 
 
3.1 (1.2-7.9) 
Von Dadelszen, et al/200 Case control National High Blood
Pressure Education 
Program criteria 
CMV+C. pneumoniae CMV – IgG ELISA 
Fluorescent detection  
Ca: 6/9 (66.7) 
Co: 46/113 (40.7) 
2.9 (0.7-12.2) 
(Calculated in  
Meta-Analysis) 
4.7.2. Meta Analysis (II) 
 
Figure 4 shows a forest plot comparing odds of preeclampsia among women with either bacterial 
or viral infections during pregnancy. A forest plot illustrates the contribution of each study to the 
meta-analysis (its weight) and is represented by the area of a box whose center represents the 
size of effect estimated from that study (point estimate).(180) Pooled results revealed a statistically 
significant association of maternal infections with preeclampsia (OR 2.1, 95% CI 1.8-2.6) (Fig. 
3), with no evidence of heterogeneity (Q = 7.5, p = 0.3), nor indication of publication bias (Fig. 
4). 
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Figure 2: Association Between Bacterial and Viral Infections and Preeclampsia. Black squares and horizontal 
lines denote odds ratios and 95% confidence intervals for each study. The size of the black squares reflects 
the weight of each study. The Diamond shape denotes pooled odds ratio and 95% CI.  
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Figure 3: Funnel Plot (with pseudo 95% CI) to detect publication bias for studies exploring the association 
between maternal infection and preeclampsia. Odds ratios are presented on a logarithmic scale. Egger's test 
of publication bias: p=0.23 
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4.8.   DISCUSSION (II) 
Pooling of relevant epidemiologic data revealed a two-fold increased risk of preeclampsia 
associated with bacterial and viral infections. This finding is consistent with results obtained 
from individual studies. However, limitations of meta-analytic reviews should be considered 
when interpreting results. These limitations generally fall into two categories: 1) limitations 
carried over from when studies were originally conducted, and 2) those related to the conduct of 
the meta-analysis.  
We addressed the first limitation, by defining a priori, inclusion and exclusion criteria. 
An important inclusion criterion required that a uniform preeclampsia diagnosis was 
implemented in all studies included in the meta-analysis. By doing so, we were reasonably 
certain that preeclampsia was defined consistently, which made it possible to make comparisons 
between studies. In the past, lack of consistency in defining preeclampsia often resulted in the 
erroneous inclusion of women with superimposed preeclampsia or women with underlying 
maternal disease such as, chronic hypertension and diabetes mellitus. Inclusion of a higher risk 
population can result in overestimation of preeclampsia incidence and can possibly inflate risk 
estimates.  
Although there was no evidence of heterogeneity in this review, quality of meta-analytic results 
are nevertheless influenced by the quality of individual studies. If potential confounders were not 
adequately addressed when studies were originally carried out, combined results will inevitably 
reflect these limitations. This is of particular concern, since adjustment of confounders is not 
possible with aggregate data. However, given the consistency of risk estimates obtained across 
studies, it is unlikely that results from this review may be confounded by factors that were not 
controlled for originally.   
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 The second limitation includes bias stemming from the conduct of a meta-analysis, such as 
publication bias. Publication bias is the tendency on the parts of investigators, reviewers, and 
editors to submit or accept manuscripts for publication based on the direction or strength of the 
study findings.(48) Typically this involves a higher acceptance rate of studies showing statistically 
significant results. In a meta-analysis, this type of bias can have the effect of skewing meta-
analytic reviews toward a positive result. Inspection of the funnel plot in Fig.4 shows a 
symmetrical distribution of study results (shown in Fig. 4 as log odds ratio), we therefore, do not 
believe publication bias was a limitation in this review. 
 
4.9.   CONCLUSION (II) 
Individual retrospective, case control and prospective studies have reported on the relationship 
between maternal infections and preeclampsia. Our combined results confirm these study 
findings. Preeclampsia is associated with an excessive intravascular, maternal inflammatory 
response. The cause of inflammation is not completely understood. However, infection clearly 
stimulates the immune system and may provide a ready explanation for preeclampsia-related 
inflammation.    
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 4.10. METHODS (III) 
 
4.10.1.    NSFG Survey design (III) 
 
Study III analyzed data collected in Cycle 5 of NSFG conducted between January and October 
1995. The NSFG survey was designed and administered by the National Center for Health 
Statistics (NCHS), and represented a national probability sample of 10,847 civilian, non-
institutionalized women between the ages of 15 and 44 years. The NSFG sample was drawn 
from 14,000 households interviewed in the 1993 National Health Interview Survey (NHIS). 
NSFG was conducted to produce national estimates of factors related to pregnancy and birth 
rates, including sexual activity, contraceptive use, infertility, and other health and health 
behavior related characteristics for the entire population of 60.2 million women 15-44 years of 
age (137). In NSFG, the Primary Sampling Units, or PSU’s, included all of the largest 
Metropolitan areas in the US. NSFG had 198 PSU’s. Written informed consent was obtained 
from each participant before interviews were undertaken. 
Of the 10,847 women who completed interviews, 6,483 were White, 2,466 were African 
American, 1,533 Hispanic and 365 were from other racial/ethnic groups. The final response rate 
for Cycle 5 of the NSFG was 81.9%. (141) Non-response rate (18.1%) was primarily due to an 
inability to locate sampled women. Missing data (don’t know, refused, or not ascertained 
responses) were imputed, by matching reported data from a similar woman in the NSFG or the 
National Health Interview Survey (NHIS) to a woman with missing data. Less than one percent 
of the cases received an imputed value. (141)
NSFG data consists of two main data files: 1) Public Use File, and 2) the Omitted Items 
files. The Public Use File contains background information, pregnancy and a variety of socio-
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 demographic information, and the Omitted Items File consists of information on abortions, 
STDs, sexual risk taking behaviors, and other reproductive health measures. 
4.10.2.    Data collection (III) 
 
Detailed and structured interviews were conducted in respondents’ homes by trained 
interviewers with the aid of a computer assisted personal interviewing program (CAPI) installed 
on laptop computers. The CAPI program aided the interview process by selecting questions that 
were appropriate for each respondent, and incorporating skip patterns based on the intent and 
logic of questions. This program also assessed validity of responses, which helped to increase the 
quality of the data. On average, interviews took one hour and 43 minutes to complete. To ensure 
respondents’ anonymity when answering sensitive questionnaire items, they were given the 
choice of using either an interviewer-administered or a self-administered interview mode. The 
self-administered mode involved the use of an audio computer-assisted self-interviewing process 
(Audio CASI). With Audio CASI, respondents heard the questions through headphones and self-
entered answers into a laptop computer.  
4.10.3.    Study design (III) 
 
The NSFG dataset contained records of 21,332 pregnancies reported by 10,847 respondents. 
Years in which pregnancies occurred ranged from 1964 to 1995. Of these records, case control 
designation was complete for only women who reported pregnancies between the years 1991 and 
1995. This left 1,565 women, including 322 preeclampsia cases and 1,243 normotensive controls 
available for analysis. The prevalence of preeclampsia in the overall NSFG sample (Public Use 
File) was 1.5% (322/21,332). We then merged the Public Use File (containing socio-
demographic and pregnancy data) with the Omitted Items File (containing STD and behavior-
related data) by case identification number.  
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 Out of the total 10,847 NSFG respondents, 434 women reported genital warts (4.0%), 215 
genital herpes (2.0%), 490 Chlamydia trachomatis (4.5%) and 220 Gonorrhea (2.0%). However, 
because case control data were only available for the years 1991 through 1995, merging of STD 
data was limited to this time frame. The remaining years with available STD data were excluded 
from this analysis. The final sample consisted of 353 records with complete STD data for the 
period 1991 to 1995. 
We also conducted secondary analysis on a subset of NSFG data. For this subset, we 
selected only primiparous respondents who reported single gestation pregnancies, no history of 
chronic hypertension, no history of gestational diabetes, and who were matched on age. Records 
missing complete STD information were excluded from this merged file as well. We were left 
with 340 records available for secondary analysis, which included 98 preeclamptics and 242 
normotensives. This sub-sample provided approximately a 1:3 case control ratio. 
The main outcomes in both analyses were preeclampsia and self-reported viral (genital warts, 
genital herpes) and bacterial (Gonorrhea and Chlamydia) infections. 
 Variable Definitions: Preeclampsia was defined by responses to the question: “During 
your pregnancy, did you have a medical problem that required medical attention beyond routine 
prenatal care, such as pregnancy-related high blood pressure, also known as preeclampsia?” This 
question was followed by a more detailed description of preeclampsia symptoms: “High blood 
pressure, which may be accompanied by proteinuria (protein buildup in urine) or edema (water 
retention and swelling), due to pregnancy or the influence of a recent pregnancy.” 
  Bacterial and viral infections were ascertained from responses to the question: “Has a 
doctor or other medical provider ever told you that you had genital warts, genital herpes 
Gonorrhea, Chlamydia? Interviewers followed the question with a description of the infection. 
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 For example for genital warts infection: “genital warts are usually painless warts on the vulva, 
cervix, or inside the vagina, caused by a virus (Human Papilloma) that is usually sexually 
transmitted.”  For genital herpes infection: “Genital Herpes is caused by a virus than can be 
sexually transmitted (Herpes Simplex Type 2). It should not be confused with herpes that causes 
cold sores or chicken pox (Herpes Simplex Type 1). In women, genital herpes causes sores on 
the cervix, vagina, and external genital area, and are sometimes painful and/or swollen.” For 
Chlamydia: “Chlamydia is a sexually transmitted disease caused by a bacterial infection 
(Chlamydia trachomatis) and treated with antibiotic drugs. This infection often shows no 
symptoms in women.” For Gonorrhea infection: “Gonorrhea, also known as ‘GC’ or ‘Clap’ is 
one of the most common sexually transmitted diseases and is caused by a bacterial infection 
(Neisseria gonorrhoeae) and treated with antibiotic drugs.” 
Socio-demographic Risk Factors: We created a three-category race variable (Non-
Hispanic white, Non-Hispanic Black, and Hispanic) by combining the question related to 
ethnicity (“Are you of Hispanic or Spanish origin?), with the question designed to determine race 
(“Which of these groups: Alaskan Native or American Indian, Asian or Pacific Islander, Black, 
White would you say best describes your racial background?”).  
Marital status was categorized as: “currently married, not married but living with a 
partner or boyfriend, widowed, divorced, separated or never married.”  Level of education was 
ascertained from the question: “What is the highest grade or year of regular school you have ever 
attended. Possible responses were: Elementary/Junior High School (including 1st to 8th grade), 
High School (9th to 12th grade), and College and Graduate Professional School (1-7 years, or 
more).”  
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 Behavioral Risk Factors: Aside from well-documented risk factors for preeclampsia 
including: 1) primiparity; 2) age; 3) low socioeconomic status; and 4) cigarette smoking, we 
obtained covariate information that may relate to the likelihood of infection. For example, we 
examined sexual behaviors, including age of sexual debut, number of sexual partners, frequency 
of sexual intercourse over the previous month, contraceptive use (barrier and non-barrier), length 
of cohabitation, and whether partner engaged in sexual relationships with other females or men. 
We also explored factors that may interact with sexual risk taking, such as IV drug use, sharing 
of needles, and having a partner who shared needles with others. 
Statistical Analysis: We used STATA statistical software to merge, clean, and recode 
Public Use and Omitted Files variables. NSFG sample was not a simple random sample, in 
which all members of the population had an equal chance of being selected. To account for this, 
NSFG employed a sampling strategy that used weights designed to produce unbiased population 
estimates. The weights adjusted for: 1) the different sampling rates for Hispanic, black, and other 
women, 2) for non-response, and 3) for coverage rates. We therefore used STATA that 
accommodates unequal selection probabilities. With STATA we conducted both univariate and 
multivariate analyses of NSFG data and generated appropriate standard errors and p-values.  
The a priori hypotheses for both primary and secondary analyses were that maternal viral 
infection denoted risk of preeclampsia, and sociodemographic, behavioral and clinical factors 
interacted with infection to trigger preeclampsia. Categorical variables were created for each 
bacterial and viral infection (coded yes=1/no=0) and summarized as frequencies by case control 
status. Continuous variables were summarized by means and standard deviations, and 
statistically significant differences determined by the Student’s t-test for variables that were 
normally distributed and the Wilcoxon test used for non-normally distributed continuous 
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 variables. For both primary and secondary analyses, variables that were missing 80% or more 
responses were excluded from logistic regression analyses (see Appendix A and B). 
Univariate logistic regression analyses were used to explore whether genital warts, 
genital herpes, C. trachomatis and Gonorrhea infections, socio-demographic, and behavioral 
characteristics were associated with preeclampsia. Variables were entered one at a time, and 
individual log-likelihoods compared. Variables with p-values of 0.20 were considered important 
variables for inclusion in subsequent multivariate models.  
Confounding was assessed, by determining whether univariate odds ratios were significantly 
altered (> 10%) upon addition of other relevant variables. Potential confounders included 
preeclampsia- and STD risk factors selected on the basis of previous literature, and biologic 
plausibility. Multicollinearity was accounted for by eliminating variables with redundant 
information, thereby reducing model variance. 
Preeclampsia was considered as outcome variable in univariate and multivariate 
regression analyses. Bacterial (Gonorrhea and Chlamydia), viral (genital warts, genital herpes) 
infections, socio-demographic, known preeclampsia risk factors (age, race, parity, multiple 
gestation pregnancies, gestational diabetes, hypertension) and health behavior variables were 
included in the multiple logistic regression models and results expressed as adjusted odds ratios 
and 95% confidence intervals. We followed the same model building strategy for the secondary 
analysis, but did not make adjustments for known preeclampsia risk factors in multivariate 
analyses, since we had already matched on them at the design stage. 
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 4.11. RESULTS (III) 
4.11.1.    Socio-demographic and health behavior characteristics (III) 
As shown in Table 14, with the exception of income, cases and controls differed significantly on 
socio-demographic characteristics including region of residence, race, education, and marital 
status. Substance use (smoking) and abuse (IV drug use) were not significantly different. In 
general, the majority of sample respondents described themselves as non-Hispanic White (51.6% 
of cases and 63.1% of controls), while 30.9% of cases and 20.2% of controls were non-Hispanic 
Black. Hispanics accounted for 17.5% of cases and 16.7% of controls. The age of preeclampsia 
respondents ranged from 14.3 to 44.4 years (mean 26.5, SD 5.8) and 12.8 to 43.8 years for 
normotensives (mean 28.5, SD 6.3). 
More than half of cases (59.8%) and controls (73.3%) were married, and the majority 
completed high school education. Of the single respondents, almost half cohabitated with a 
partner (41.8% of cases and 48.8% of controls), and half lived alone.  
As expected, low birth weight babies were significantly more common among women who 
reported preeclampsia (18.2%) than normal pregnancies (7.8%, p<0.001). Prenatal care in the 
first six months of pregnancy was also commoner among women with preeclampsia (92.9% of 
cases versus 77.5% of controls, p < 0.001), and they were also, more often, recipients of 
Medicaid (p <0.001), and AFDC assistance (p=0.04). Very few women reported smoking during 
pregnancy.  
Among barrier contraceptive users, cases (3.2%) used female condoms more often than 
controls (0.5%) (p=0.07), whereas no case control differences were observed in the use of male 
condoms (91.6% and 87.6%, respectively, p=0.31). Among non-barrier contraceptive users, 
women with preeclampsia used the rhythm method more often than controls (32.6% versus 
19.4%, respectively, p=0.02). 
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 Although not statistically significant, women with preeclampsia reported with greater 
frequency having had only one lifetime sexual partner compared to normotensive women (19.0% 
vs 9.3%). Very few women reported high-risk practices, including IV drug use (1.0% of cases 
versus 2.1% of controls), sharing of needles with others (0.3% of cases and 0.2% of controls), or 
sexual partners who had sex with men (0 % of cases and 2.2 % of controls). However, a slightly 
larger proportion of women suspected partners of having sexual intercourse with other women 
(17.8% of cases and 21.3% of controls). Of the preeclampsia cases, 16.8% reported being tested 
or treated for STDs in the previous 12 months, compared to 16.1% of controls. Additionally, one 
third of cases (30.5%), and controls (31.1%) reported being tested or treated for vaginal, UTI, or 
Pelvic infections in the previous 12 months. No case control differences were observed for 
frequencies of reported miscarriages or abortions.  
In general, racial differences were seen for both socio-demographic, and behavior 
characteristics (Table 16). For example, Non-Hispanic blacks reported receiving Medicaid, 
AFDC and Food Stamp assistance significantly more often compared to Non-Hispanic Whites 
and Hispanics. Hispanics reported condom use significantly less often than Non-Hispanic whites 
and blacks (p<0.001). Non-Hispanic blacks, on the other hand, reported younger age of sexual 
debut (p=0.02), and larger numbers of sexual partners (p=0.001) with greater frequency 
compared to Hispanics and Non-Hispanic Whites. 
Hispanics did not report any genital warts or gonorrhea infections. The prevalence of 
gonorrhea was significantly higher among Non-Hispanic Blacks (7.3% versus 0% for Hispanics 
and 1.0% for Non-Hispanic Whites, p=0.02). 
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 4.11.2.    Self-reported viral and bacterial infection (III) 
Table 15 summarizes prevalence of maternal infection by case control status. Among the 102 
preeclampsia cases with complete STD data, ten reported being told by a medical provider that 
they had genital warts (9.8%), seven respondents were told they had genital herpes (6.9%), 
eleven were told they had Chlamydia (10.8%), and only one reported Gonorrhea (1.0%). Among 
the 251 controls with complete STD data, eleven women reported Genital Warts infections 
(4.4%), six had Genital Herpes (2.4%), fourteen reported Chlamydia (5.6%), and six women 
reported Gonorrhea (2.4%). Both in the overall sample population and among women with 
preeclampsia, those with genital warts, genital herpes, C. trachomatis, or N. Gonorrhoeae 
infections, reported greater numbers of sexual partners, whereas those with no infections 
reported having had only one sexual partner.  
Tables 17, 18, and 19 list results from logistic regression analyses, in which we examined 
the association between maternal infection, socio-demographic, and behavioral factors and the 
risk of preeclampsia. Our findings suggest that among women who reported genital warts, 
genital herpes, and Chlamydia trachomatis infections, the risk of preeclampsia was significantly 
greater (OR 2.5, 95% CI 1.2-5.4; OR 3.6, 95% CI 1.3-9.9; OR 1.9, 95% CI 1.1-3.1, respectively) 
in comparison to healthy pregnant women. These associations remained significant after 
adjusting for socio-demographic, behavioral, and infection-related risk factors (OR 3.0, 95% CI 
1.1-8.5; OR 7.2, 95% CI 1.2-42.5; OR 5.2, 95% CI 1.3-20.2, respectively). Gonorrhea was not 
associated with preeclampsia neither in univariate or multivariate models. 
We obtained similar findings in secondary analysis (Table 19). Genital warts, genital herpes 
and Chlamydia trachomatis significantly increased the risk of preeclampsia. In analysis set 1, 
Chlamydia (OR 1.1, 95% CI 0.4-3.0) was not associated with preeclampsia in univariate model. 
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 However, after adjusting for socio-demographic and behavioral factors, Chlamydia was 
associated with 2.6-fold increased risk of preeclampsia (OR 2.6, 95% CI 0.5-13.2), but this 
association was not statistically significant. In contrast, Gonorrhea appeared to lower the risk of 
preeclampsia (OR 0.3, 95% CI 0.01-8.3).  
 
Table 14: Percent Distribution of Self-reported Socio-demographic, and Behavioral 
Characteristics of Preeclampsia and Normotensive (Paper III) 
Variable Preeclampsia  
Cases (%)  
(N=322) 
Normotensive 
Controls (%) 
(N=1,243) 
 
 
          P* 
Socio-demographic Characteristics 
Region 
     Northeast 
     Midwest 
     South 
     West 
 
17.7 
23.3 
38.8 
20.2 
 
19.2 
25.6 
29.7 
25.5 
 
 
0.01 
 
 
 
 
Race 
     White, non-Hispanic 
     Black, non-Hispanic 
     Hispanic 
 
 
51.6 
30.9 
17.5 
 
 
63.1 
20.2 
16.7 
 
<0.001 
 
 
 
Marital Status 
   Married or living w/ partner   
   Single, or Living Alone 
 
 
59.6 
40.1 
 
73.3 
26.7 
 
<0.001 
 
Income 
    > 70K 
   30K-70K 
    < 30K 
Missing 
 
4.0 
11.2 
11.2 
73.6 
 
2.1 
6.8 
4.7 
86.4 
 
0.42 
 
Education 
    < High School 
      High School 
    College/Graduate  
 
 
22.7 
73.9 
3.4 
 
 
16.3 
79.5 
4.2 
 
 
0.03 
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 Table 14 (cont’d) 
 
Cases                   Controls                   p
Health Care Utilization and Food Assistance 
Medicare/Medicaid 
    No 
    Yes 
 
 
58.3 
41.7 
 
73.4 
26.6 
 
<0.001 
Foodstamp 
    No 
    Yes 
 
 
79.8 
20.2 
 
83.8 
16.2 
 
0.41 
AFDC 
    No 
    Yes 
Missing 
 
24.5 
4.7 
70.8 
 
14.2 
1.2 
84.6 
 
0.04 
Received Prenatal Care 
     No 
     Yes 
Missing 
 
          6.8 
92.9 
0.3 
 
22.5 
77.5 
0.1 
 
<0.001 
Time Began Prenatal Care 
     First Trimester 
     Second Trimester 
 
92.6 
  7.4 
 
95.0 
   5.0 
 
0.12 
 
Trimester of Pregnancy 
     First Trimester 
     Second Trimester 
    Third Trimester 
 
49.3 
   0.0 
  50.7 
 
 72.8 
    3.1 
  24.1 
 
<0.001 
 
Obstetric Characteristics and Pregnancy Outcomes 
Treated for Miscarriage 
       No 
       Yes 
 
 
72.0 
28.0 
 
80.1 
20.0 
 
0.002 
Any Abortion 
       No 
       Yes 
 
 
94.7 
  5.3 
 
94.2 
 5.8 
 
0.86 
Low Birth Weight Baby 
     No 
     Yes 
 
 
81.9 
18.2 
 
92.2 
  7.8 
 
0.001 
Baby’s Gender 
     Male 
     Female 
 
49.6 
50.4 
 
49.3 
50.7 
 
0.93 
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 Table 14 (cont’d) 
 
 
Non-Barrier Birth Control Methods          Cases                     Controls                  p
 
Oral Contraceptive 
       No 
       Yes 
 
 
16.8 
83.2 
 
19.7 
80.3 
 
0.56 
 
Depo-Provera 
       No 
       Yes 
 
 
85.3 
14.7 
 
90.7 
 9.3 
 
0.17 
Withdrawal Method 
       No 
       Yes 
 
 
52.6 
47.4 
 
54.4 
45.6 
 
0.78 
Rhythm Method 
       No 
       Yes 
 
 
67.4 
32.6 
 
80.3 
19.7 
 
0.02 
 
 
Barrier Birth Control Methods 
Male Condom Use 
       No 
       Yes 
 
 
8.4 
91.6 
 
12.4 
87.6 
 
0.31 
Female Condom Use 
       No 
       Yes 
 
 
96.8 
  3.2 
 
99.5 
  0.5 
 
0.07 
Spermicide Use 
       No 
       Yes 
 
 
85.3 
14.7 
 
86.0 
14.0 
 
0.87 
Diaphragm Use 
       No 
       Yes 
 
 
86.3 
13.7 
 
92.2 
 7.8 
 
0.11 
IUD 
       No 
       Yes 
 
 
99.0 
  1.0 
 
98.5 
 1.5 
 
0.73 
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 Table 14 (cont’d) 
 
High Risk Behaviors                                      Cases                   Controls                    p 
 
   Frequency Intercourse 
       ≤ Once a month 
       2-3 a month 
       Once a week 
       2-3 times a week 
       ≥ 4 times a week 
 
 
15.0 
30.8 
23.5 
29.6 
  1.2 
 
          15.8 
25.5 
21.8 
29.1 
 7.9 
 
0.27 
Number of  Sexual Partners 
     ≤ 1 
     2-3 
     4-5 
     >5 
 
 
19.0 
75.9 
  2.6 
  2.6 
 
  9.3 
88.3 
 0.7 
 1.7 
 
<0.001 
Age of First Sexual Intercourse 
    ≤ 15 
    15-20 
    ≥ 21 
 
 
20.0 
62.1 
17.9 
 
26.3 
57.4 
16.3 
 
0.50 
IV Drug Use 
     No 
     Yes 
 
99.0 
  1.0 
 
97.9 
  2.1 
 
0.67 
Shared Needles 
     No 
     Yes 
 
0.0 
      100.0 
 
100.0 
    0.0 
 
0.20 
Partner Had Sex with Men 
     No 
     Yes 
 
      100.0 
0.0 
 
  97.8 
    2.2 
 
0.31 
Partner Had Sex with Other Females 
     No 
     Yes 
 
82.2 
17.8 
 
78.7 
21.3 
 
0.53 
Tested or Treated for STD in Past 12 
Months 
       No 
       Yes 
 
 
 
83.2 
16.8 
 
 
83.9 
16.1 
 
 
0.87 
Tested or Treated for Vaginal, UTI, or 
Pelvic Infection in Past 12 months 
       No 
       Yes 
 
 
 
69.5 
30.5 
 
 
68.9 
31.1 
 
 
0.92 
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 Table 14 (cont’d)                                           Cases                     Controls                    p      
 
Chances of Being Infected With HIV 
       High 
       Medium 
       Low 
       None 
 
 
0.0 
3.5 
12.1 
84.5 
 
0.9 
0.4 
22.2 
75.9 
 
0.23 
Substance Use 
 
Smoked During Pregnancy 
      No 
      Yes 
 
15.3 
10.2 
 
22.3 
19.8 
 
0.52 
 
 
 
* Chi-square or Fisher’s Exact test p-values 
 
Table 15: Number and Percent Distribution of Maternal Infection by Case 
Control Status (Paper III) 
 
Variable Preeclampsia Cases 
N=102* 
n (%) 
Normotensive Controls 
N=251* 
n (%) 
Genital Warts 
      No 
      Yes 
 
 
92 (90.2) 
10  (9.8) 
 
240 (95.6) 
11 (4.4) 
Genital Herpes 
      No 
      Yes 
 
 
95 (93.1) 
7 (6.9) 
 
245 (97.6) 
6 (2.4) 
Chlamydia 
      No 
      Yes 
 
 
91 (89.2) 
11 (10.8) 
 
 
237 (94.4) 
14 (5.6) 
Gonorrhea 
      No 
      Yes 
 
 
101 (99.0) 
1 (1.0) 
 
245 (97.6) 
6 (2.4) 
 
* Sample size available to determine prevalence of infection across case control status.  
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Table 16: Frequencies and Percentages of  
Selected Maternal Characteristics by Race Groups (Paper III) 
   
                                        Non-Hispanic            Non-Hispanic Hispanic  
              White                Black 
                                     __________________________________________________ 
                      n(%)        N  n(%)     N     n(%)      N 
Genital Warts              19 (8.1)     235 2 (2.9)     69      0 (0)   40  
Genital Herpes    11 (4.7)     235  0 (0)     69         2 (5.0)   40 
Chlamydia   18 (7.7)     235  4 (5.8)     69         3 (7.5)   40 
Gonorrhea*       2 (0.9)     235  5 (7.3)     69         0 (0)   40 
Male Condom Use**           177 (92.2)   192          52 (96.3)    54       20 (58.8)   34 
Female Condom Use      1 (0.5)     192  2 (3.7)     54      1 (2.9)   34 
Rhythm Method  50 (26.0)   192  8 (14.8)    54      9 (26.5)   34 
Age first had sex* 
     ≤ 15 years   41 (21.7)   189           21 (38.9)    54      6 (17.7)   34 
    15-20 years                      116 (61.4)   189           30 (55.6)   54       19 (55.9)   34  
    ≥ 21 years   32 (16.9)   189             3 (5.6)     54      9 (26.5)   34  
 
 
 
 
 
 
 
 
 
 
 
 96
  
Table 16 (cont’d) 
 
                                       Non-Hispanic            Non-Hispanic            Hispanic  
              White                Black 
                                     __________________________________________________ 
                      n(%)        N  n(%)     N     n(%)      N 
_________________________________________________________________________ 
# Sexual Partners in  
past 5 years** 
    ≤ 1                       124 (13.8)   901           19 (5.7)     331    23 (9.1)          252      
    2-3                        754 (83.7)   901         296 (89.4)   331  224 (88.9)        252  
    4-5        9 (1.0)     901             6 (1.8)     331     1 (0.4)          252    
    > 5    14 (1.6)     901           10 (3.0)     331     4 (1.6)          252  
Age at pregnancy** 
    < 19 years   33 (3.8)     879           26 (8.3)      312   10 (4.3)          235  
    19-34 years                      684 (77.8)   879         246 (78.9)    312 187 (79.6)        235  
    > 34 years                      162 (18.4)   879           40 (12.8)    312   38 (16.2)        235  
Total Income 
    < 30K   56 (32.6)   172           21 (47.7)      44   15 (48.4)    31  
    30K-70K   86 (50.0)   172           21 (47.7)      44   11 (35.5)    31  
    >70 K   30 (17.4)   172   2 (4.6)        44     5 (16.1)    31 
Education** 
    < High School  46 (4.9)     927              3 (0.9)      343    8    (3.1)        257   
    High School                     109 (11.8)   927            82 (23.9)    343  83  (32.3)       257  
    ≥ College                      772 (83.3)   927          258 (75.2)    343 156  (64.6)      257 
Medicaid**                       180 (19.5)   924          188 (55.0)    342   88 (34.4)       256 
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 Table 16 (cont’d) 
 
                                      Non-Hispanic            Non-Hispanic         Hispanic  
              White                Black 
                                     __________________________________________________ 
                      n(%)        N  n(%)     N     n(%)      N  
_________________________________________________________________________
AFDC**              12 (6.3)     190           13 (24.5)      53     3 (8.8)           34 
Food Stamp**              22 (11.6)     190          22 (41.5)      53    5 (14.7)         34 
Get PNC                       764 (82.4)     927        261 (76.5)    341  204 (79.4)     257 
PNC 1st 6 mos              29 (3.8)       762          27 (10.3)    261    13 (6.4)      204 
Parity* 
    One                        678 (73.1)    927         262 (76.4)     343  207 (80.5)    257  
    Two                        249 (26.9)    927           81 (23.6)     343    50 (19.5)    257    
*    Chi-square or Fisher’s Exact test p-values  < 0.05 
**  p values < 0.001 
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 Table 17: Analysis Set 1: Univariate Odds Ratios (OR) and 95% confidence intervals (CI) 
of Preeclampsia According to Self-reported Viral and Bacterial Infections, Socio-
demographic, and Sexual Behavior Characteristics  (Paper III) 
                       
                                                                                Univariate(b)  
    __________________________________________ 
      OR  95% CI   p 
 
Genital Warts    2.5  1.2–5.4  0.02   
Genital Herpes   3.6   1.3-9.9         0.01   
Gonorrhea    0.7  0.1-3.3          0.62   
Chlamydia    1.9  1.1-3.1                        0.02   
Race  
   Non-Hispanic Black  1.7  1.3-2.2                       <0.001   
   Hispanic    1.4  0.9-2.1          0.16   
Education 
   < High School   1.4  0.8-2.7              0.28   
   High School    0.9  0.5-1.8              0.90 
Married    0.6  0.4-0.9              0.02   
Age at Pregnancy 
   19-34    2.5  1.3-4.9              0.01 
   > 34     3.5  1.4-8.8              0.01 
First Trimester Pregnancy  3.5  2.8-4.4                   <0.001 
Sexual Partners 
   2-3 partners    0.5  0.3-0.7                   <0.001 
   4-5 partners    0.5  0.2-1.5              0.21   
   > 5 partners    0.6  0.4-0.7                   <0.001   
Age 1st Sex 
     15-20 years   1.5  0.5-4.0   0.47   
     ≥ 21 years      1.5  0.9-2.4   0.06   
Partner Shared Needles  2.0  0.4-11.1  0.43 
Smoking    0.4  0.3-0.7   0.001   
Medicare/Medicaid   1.8  1.4-2.3            <0.001  
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 Table 17 (cont’d) 
 
                                                                           Univariate(b)  
    __________________________________________ 
      OR  95% CI   p 
______________________________________________________________________________
Prenatal Care (PNC)   4.2  2.5-7.3                       <0.001 
Began PNC in 2nd trimester  1.3  0.5-2.9   0.59 
Gestational Diabetes   1.2  0.9-1.8   0.22 
 Pregnancy Order    
    1st      2.7   1.6-4.5            <0.001 
    2nd       1.3   0.9-1.8   0.25 
    3rd      1.4   1.3-1.4            <0.001 
    4th     1.3   0.7-2.3    0.44  
Treated for UTI   1.1   0.7-1.8    0.60 
Referent category for race is Non-Hispanic White; for Education is High School; for Marital Status is married; for 
Partners in past 5 yrs is one partner; for Age 1st sex is less than 15; for Frequency Sex is ≤ 1 x/month. The reference 
category for viral and bacterial infection, Partner IV Drug Use, Smoking, Medicaid, Barrier and Non-barrier 
contraceptives is “No”. 
 
 
Table 18: Analysis Set 1: Multivariate Odds Ratios (OR) and 95% confidence intervals 
(CI) of Preeclampsia According to Self-reported Viral and Bacterial Infections, Socio-
demographic, and Sexual Behavior Characteristics  (Paper III) 
                                                                         Multivariate(b)  
 Variable (a)   ________________________________ 
      OR  95% CI   p 
 
Genital Warts               3.0  1.1–8.5  0.04   
Genital Herpes   7.2   1.2-42.5            0.03   
Gonorrhea    1.0  0.5-2.0          0.98   
Chlamydia    5.2  1.3-20.2             0.02   
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Table 18 (cont’d) 
 
                                                                               Multivariate(b)  
 Variable (a)   ________________________________ 
      OR  95% CI    p  
______________________________________________________________________________
Race  
   Non-Hispanic Black  0.8  0.2-3.3              0.78   
   Hispanic    1.5  0.2-9.7        0.66  
Income 
   < 30K    3.1  1.1-9.1   0.04   
   30K-70K    1.3  0.5-3.6   0.65   
Education 
   < High School   3.0  0.3-27.5  0.34   
   High School    0.5  0.1-2.2   0.35 
Not Married    1.4  1.0-2.1              0.07   
Gestational Age   1.0  1.0-1.1                   <0.001 
All Sexual Partners 
   2-3     0.9  0.5-1.8                    0.76 
   4-5     1.2  0.1-20.5  0.88   
   > 5     0.6  0.2-1.9                    0.40   
Frequency Intercourse 
     2-3 x/month   1.1  0.2-5.8   0.91   
     1 x/week    2.8  0.9-8.2   0.07 
     ≥ 2x/week    2.1  1.2-3.7              0.01   
Partner Had Sex w/ other females 2.6  0.8-7.9   0.11 
Smoking    0.3  0.2-0.6              0.001   
Medicare/Medicaid   3.2  2.5-4.0            <0.001   
Food Stamp    0.4  0.3-0.7            <0.001   
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Table 18 (cont’d) 
 
                                                                              Multivariate(b)  
 Variable (a)   ________________________________ 
      OR  95% CI   p 
_____________________________________________________________________________ 
Male Condom               4.5  2.0-10.0           <0.001   
Rhythm Method   3.5  2.2-5.8            <0.001 
Tested or treated for UTI  0.6  0.2-1.4   0.21 
Tested or treated for STD  0.6  0.3-1.5   0.26 
 
(b) Adjusted for all other variables in the model, and additionally for age at pregnancy (three-year categories of <19 
years to >34 years), Region (Northeast, Midwest, South, and West), Length of cohabitation, Gestational Diabetes, 
and High Blood Pressure 
 
Table 19: Analysis Set 2: Univariate and Multivariate-adjusted Odds Ratios (OR) and 95% 
confidence intervals (CI) of Preeclampsia According to Viral and Bacterial Infections 
(Paper III)   
                
                                               Univariate(a)    Multivariate(b) 
   ______________________  ______________________ 
     OR (95% CI) p     OR (95% CI)  p 
Genital Warts  2.6 (1.1–6.6)             0.04  2.9 (1.1-7.5)           0.03 
Genital Herpes 6.7 (1.2-38.2)           0.03  5.9 (1.1-32.8)           0.04 
Gonorrhea  0.1 (0.0-1.3)             0.08  0.3 (0.0-8.3)           0.46 
Chlamydia  1.1 (0.4-3.0)             0.84  2.6 (0.5-13.2)            0.25 
 
(a) Cases and controls were matched for age, parity, and multiple gestation pregnancies. Cases and controls who 
reported hypertension, diabetes, and gestational diabetes were excluded from analysis 
(b) Adjusted for Region (Northwest, Midwest, South, and West), prenatal care, gestational age, marital status, 
education, race, Medicaid, Food Stamp, AFDC, smoking, Barrier (condom, spermicide, diaphragm, cervical cap, 
sponge) /Non-Barrier (oral contraceptive, Depo-Provera, withdrawal and no birth control method) contraceptive use, 
cohabitation with partner, number of sexual partners in previous five years, frequency of intercourse (in previous 
month), IV drug use  
 102
 4.12. DISCUSSION (III) 
We observed significant associations between Genital Warts, Genital Herpes, and C. trachomatis 
and preeclampsia, which persisted after adjusting for both preeclampsia- and behavior-related 
risk factors. This study is, to our knowledge, the first study to explore the relationship between 
Genital Warts and Gonorrhea infections and the risk of preeclampsia. Previous epidemiologic 
studies have reported similar associations with respect to Herpes viruses (HSV-1, HSV-2, CMV, 
and EBV) and Chlamydia (C. pneumoniae), (80)(83)(86)(125)(157)(186)(194) but none have explored 
factors that could both affect infection status and interact with infection to trigger preeclampsia. 
Additionally, our results are consistent with previous studies that showed a protective effect of 
smoking (OR 0.3, 95% CI 0.2-0.6), which persisted after adjusting for socio-demographic, 
behavioral and infection-related risk factors. 
A major strength of this study is that it is population-based, and therefore findings can be 
generalized to the general population. Furthermore, we were able to obtain detailed socio-
demographic and STD-related characteristics to explore the association between maternal STD 
infection and preeclampsia and had sufficient power to detect significant associations.  
A few study limitations should be considered when interpreting results. First, the present 
study relies on self-reports of sexually transmitted diseases and health risk behaviors, and is 
therefore prone to many forms of bias, including recall and social desirability bias. Ultimately, 
recall bias can result in both STD and health risk behaviors to be under or over-reported, either 
because respondents could not recall information or in the case of infection, were unaware of 
infection status. There is also the possibility for information to be withheld, if respondents 
perceived that their identities would not be kept anonymous or that their responses were not held 
confidential. Social desirability bias can occur if respondents perceived that investigators 
preferred certain attitudes or behaviors. (35)  
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 NSFG used several techniques to maximize accuracy of responses and ensure privacy. 
NSFG interviewers assured respondents that both their identities and responses to questionnaire 
items would be kept confidential. Sensitive questionnaire items were left to the end, therefore 
allowing interviewers the time to establish rapport with respondents.  Moreover, respondents 
were given the choice of a self-administered interview mode to answer more sensitive questions. 
They were asked at the end of interview, how likely it was that they would have given different 
answers had they chosen the interviewer-administered mode instead. Based on comparisons 
made with vital statistics and other external data, NSFG pregnancy and live birth self reports 
were found to be reliable. (141)  
A second limitation is that case assignment was based on preeclampsia self-reports. Case 
misclassification has been a concern in preeclampsia studies due to lack of consistency in 
defining this disorder. Although a far more reliable method of determining preeclampsia 
incorporates well-defined diagnostic criteria, we found that preeclampsia prevalence in the 
NSFG sample (1.5%) was similar to that obtained from many studies utilizing clinical diagnoses. 
Preeclampsia occurs in 3-10% of all pregnancies worldwide and in approximately 2-4% in the 
United States.(44)(79) Incidence varies depending on the patient population, institution and 
diagnostic criteria. For example, in a national hospital Discharge database, the rate of 
preeclampsia was 2.6%, 155) whereas the Maternal Fetal Medicine Network trial of low-dose 
aspirin in preeclampsia estimated a 6.3% incidence of preeclampsia. (169)
We believe it is unlikely that NSFG preeclampsia self-reports were widely inaccurate. 
Given the severity of preeclampsia, women may be more likely to remember whether they 
experienced a pregnancy complicated by preeclampsia. Nevertheless, it is still possible that some 
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 preeclampsia cases were misclassified. This would most likely have the effect of attenuating 
associations.      
 
4.13. CONCLUSION (III) 
Both case control and prospective studies have reported on the relationship between maternal 
infections and preeclampsia. Preeclampsia is associated with an excessive intravascular maternal 
inflammatory response. The cause of inflammation is not completely understood. However, 
infection is known to stimulate the immune system and may provide a ready explanation for 
preeclampsia-related inflammation.   
Clearly, firm conclusions cannot be drawn from self-reported STD data. Serology is a 
significantly more dependable indicator of infection. Ideally, pregnant women should be 
followed from the first through the third trimesters, with multiple blood draws available for STD 
testing. Further prospective studies are needed to understand better the temporal nature of STD 
infection and self-reported health risk behaviors. In addition data on medication use is helpful to 
determine the effect of treatment on infection and its relation to preeclampsia incidence.  
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5. PUBLIC HEALTH IMPLICATIONS 
5.1.   PAPERS I, II, III 
Our findings suggest that maternal infections, particularly HSV-1, HSV-2, CMV, Genital warts 
(HPV) and Chlamydia trachomatis, significantly increase the risk of preeclampsia. Our findings 
have important public health significance. Given the widespread prevalence of these maternal 
infections, and the potential for their prevention, identification of subgroups of women with 
modifiable behaviors might ultimately contribute to prevention strategies.  
Additionally, our research was the first to examine the relationship between primary 
herpes infections and preeclampsia. We found that seroconversion for HSV 1 / 2 or CMV during 
pregnancy, was associated with a five-fold increased risk of preeclampsia. One possible 
implication of this finding is that women who are seronegative at the onset of pregnancy may 
benefit from condom use. 
Preeclampsia is associated with an excessive intravascular, maternal inflammatory 
response. The cause of inflammation is not completely understood. However, infection is known 
to stimulate the immune system and may provide a biologically plausible explanation for 
preeclampsia-related inflammation. However, whether in utero infections may influence 
preeclampsia risk is not known. 
In addition, for most women, pregnancy represents a time in their lives when they are the 
most in contact with the health care system.  For some women, pregnancy may be the only time 
they will see a medical provider on a regular basis. Obstetricians and primary care providers 
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 have a unique opportunity to provide education and counseling to pregnant women at risk for 
STDs. 
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 APPENDIX A: FREQUENCY DISTRIBUTION FOR VARIABLES IN PAPER I 
 
 
 
 
Case control status 
 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Codes 0 = Normotensives 140 74.5 74.5 74.5 
  1 = Preeclamptics 48 25.5 25.5 100.0 
  Total 188 100.0 100.0   
 
 
Race 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
1 = Black 56 29.8 29.8 29.8 
2 = White 132 70.2 70.2 100.0 
Codes 
Total 188 100.0 100.0   
 
 
BMI category 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
1 = < 18 133 70.7 74.3 74.3 
2 = 18 to 30 3 1.6 1.7 76.0 
3 = >30 43 22.9 24.0 100.0 
Codes 
Total 179 95.2 100.0   
Missing System 9 4.8    
Total 188 100.0    
 
 
 
 
Medicare/Medicaid 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 79 42.0 42.0 42.0 
1 = Yes 109 58.0 58.0 100.0 
Codes 
Total 188 100.0 100.0   
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APPENDIX A (cont’d) 
  
 
Marital status 
 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Codes 1 = Never Married 83 44.1 44.1 44.1 
  2 = Married 105 55.9 55.9 100.0 
  Total 188 100.0 100.0   
 
 
Education 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
1 = > HS 90 47.9 47.9 47.9 
2 = < HS 98 52.1 52.1 100.0 
Codes 
Total 188 100.0 100.0   
 
 
Income Group 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 = < 10K 47 25.0 25.0 25.0 
  2 = 10-<20K 30 16.0 16.0 41.0 
  3 = 20-50K 34 18.1 18.1 59.0 
  4 = > 50K 49 26.1 26.1 85.1 
  5 = Don't Know 28 14.9 14.9 100.0 
  Total 188 100.0 100.0   
 
 
Smoking before pregnancy 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 = Yes 24 12.8 14.3 14.3 
  2 = No 22 11.7 13.1 27.4 
  3 = Don't Know 122 64.9 72.6 100.0 
  Total 168 89.4 100.0   
Missing System 20 10.6    
Total 188 100.0    
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APPENDIX A (cont’d) 
 
 
Smoking during pregnancy 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 = Yes 30 16.0 23.4 23.4 
  2 = No 12 6.4 9.4 32.8 
  3 = Don't Know 86 45.7 67.2 100.0 
  Total 128 68.1 100.0   
Missing System 60 31.9    
Total 188 100.0    
 
Time interval between blood draw 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
1 = less than 6 months 12 6.4 6.4 6.4
2 = greater or equal to 
6 months 175 93.1 93.6 100.0
Codes 
Total 187 99.5 100.0  
Missing System 1 .5    
Total 188 100.0    
 
Birth Control Pill 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 154 81.9 81.9 81.9 
1 = Yes 34 18.1 18.1 100.0 
Codes 
Total 188 100.0 100.0   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 110
 APPENDIX A (cont’d) 
 
 
 
Depoprovera 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 179 95.2 95.2 95.2 
1 = Yes 9 4.8 4.8 100.0 
Codes 
Total 188 100.0 100.0   
 
  No birth control 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 90 47.9 47.9 47.9 
1 = Yes 98 52.1 52.1 100.0 
Codes 
Total 188 100.0 100.0   
 
Non barrier contraceptive 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 35 18.6 18.6 18.6 
1 = Yes 153 81.4 81.4 100.0 
Codes 
Total 188 100.0 100.0   
 
Diaphragm 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 186 98.9 98.9 98.9 
1 = Yes 2 1.1 1.1 100.0 
Codes 
Total 188 100.0 100.0   
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 APPENDIX A (cont’d) 
 
 
 
 
Spermicide 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 169 89.9 89.9 89.9 
1 = Yes 19 10.1 10.1 100.0 
Codes 
Total 188 100.0 100.0   
 
Condom 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 104 55.3 55.3 55.3 
1 = Yes 84 44.7 44.7 100.0 
Codes 
Total 188 100.0 100.0   
  
Cervical cap 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 187 99.5 99.5 99.5 
1 = Yes 1 .5 .5 100.0 
Codes 
Total 188 100.0 100.0   
 
Sponge 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 187 99.5 99.5 99.5 
1 = Yes 1 .5 .5 100.0 
Codes 
Total 188 100.0 100.0   
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 APPENDIX A (cont’d) 
 
 
Barrier contraceptive 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 91 48.4 48.4 48.4 
1 = Yes 97 51.6 51.6 100.0 
Codes 
Total 188 100.0 100.0   
 
Any seroconversion 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 179 95.2 95.2 95.2 
1 = Yes 9 4.8 4.8 100.0 
Codes 
Total 188 100.0 100.0   
 
HSV 1 / 2 seroconversion 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 181 96.3 96.3 96.3 
1 = Yes 7 3.7 3.7 100.0 
Codes 
Total 188 100.0 100.0   
 
HSV-1 non primary infection 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 95 50.5 50.5 50.5 
1 = Yes 93 49.5 49.5 100.0 
Codes 
Total 188 100.0 100.0   
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 APPENDIX A (cont’d) 
 
 
 
 
HSV 1 / 2 non primary infection 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 91 48.4 48.4 48.4 
1 = Yes 97 51.6 51.6 100.0 
Codes 
Total 188 100.0 100.0   
 
CMV non primary infection 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 107 56.9 56.9 56.9 
1 = Yes 81 43.1 43.1 100.0 
Codes 
Total 188 100.0 100.0   
 
EBV non primary infection 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 10 5.3 5.3 5.3 
1 = Yes 178 94.7 94.7 100.0 
Codes 
Total 188 100.0 100.0   
 
HSV-1 Negative 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 100 53.2 53.2 53.2 
1 = Yes 88 46.8 46.8 100.0 
Codes 
Total 188 100.0 100.0   
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 APPENDIX A (cont’d) 
 
 
 
HSV-2 negative 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 54 28.7 28.7 28.7 
1 = Yes 134 71.3 71.3 100.0 
Codes 
Total 188 100.0 100.0   
 
HSV 1 / 2 negative 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 126 67.0 67.0 67.0 
1 = Yes 62 33.0 33.0 100.0 
Codes 
Total 188 100.0 100.0   
 
HSV-2 non primary infection 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 145 77.1 77.1 77.1 
1 = Yes 43 22.9 22.9 100.0 
Codes 
Total 188 100.0 100.0   
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 APPENDIX B: FREQUENCY DISTRIBUTION FOR VARIABLES IN PAPER III 
 
 
Analysis Set 1 
 
 
 
Preeclampsia 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 1,243 79.4 79.4 79.4 
1 = Yes 322 20.6 20.6 100.0 
Codes 
Total 1,565 100.0 100.0   
 
Parity 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
1 = Primipara 1,175 75.1 75.1 75.1 Codes 
1 = Multipara 390 24.9 24.9 100.0 
Total 1,565 100.0 100.0   
 
Pregnancy Order 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 =  First 246 15.7 15.7 15.7 
  2 = Second 223 14.3 14.3 30.0 
  3 = Third 307 19.6 19.6 49.6 
  4 = Fourth 399 25.5 25.5 75.1 
  5 = ≥ Fifth 390 24.9 24.9 100.0 
  Total 1,565 100.0 100.0   
 
Age at pregnancy 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 = < 19 years 70 4.5 4.5 4.5 
  2 = 19-34 years 1,139 72.8 72.8 77.3 
  3 = > 34 years 252 16.1 16.1 93.3 
Missing System 104 6.7 6.7  100.0  
Total 1,565 100.0 100.0    
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APPENDIX B Analysis Set 1 (cont’d) 
 
 
Genital Warts 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 332 21.2 21.2 21.2 Codes 
1 = Yes 21 1.3 1.3 22.6 
Missing System 1,212 77.4 77.4 100.0  
Total 1,565 100.0 100.0   
 
Gonnorhea 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 346 22.1 22.1 22.1 Codes 
1 = Yes 7 0.5 0.5 22.6 
Missing System 1,212 77.4 77.4 100.0  
Total 1,565 100.0 100.0   
 
Chlamydia 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 328 21.0 21.0 21.0 Codes 
1 = Yes 25 1.6 1.6 22.6 
Missing System 1,212 77.4 77.4 100.0  
Total 1,565 100.0 100.0   
 
HSV-2 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 340 21.7 21.2 21.2 Codes 
1 = Yes 13 0.8 0.8 22.0 
Missing System 1,212 77.4 77.4 100.0  
Total 1,565 100.0 100.0   
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APPENDIX B Analysis Set 1 (cont’d) 
 
 
Gestational Diabetes 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0 = No 1,415 90.4 90.4 90.4 
  1 = Yes 147 9.4 9.4 99.8 
  9 = Don't Know 1 0.1 0.1 99.9 
Missing System 2 0.1 0.1 100.0  
Total 1,565 100.0 100.0   
 
Number of Sexual Partners 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 =  ≤ 1 171 10.9 10.9 10.9 
  2 = 2-3 1,304 83.3 83.3 94.3 
  3 = 4-5 16 1.0 1.0 95.3 
  4 = > 5 29 1.9 1.9 97.1 
 Missing System 45 2.9 2.9 100.0 
  Total 1,565 100.0 100.0   
 
Frequency sexual intercourse 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 =  ≤ once/mo 38 2.4 2.4 2.4 
  2 = 2-3 / mo 67 4.3 4.3 6.7 
  3 = once/wk 55 3.5 3.5 10.2 
  4 = > 5 72 4.6 4.6 14.8 
 Missing System 1,333 85.2 85.2 100.0 
  Total 1,565 100.0 100.0   
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APPENDIX B Analysis Set 1 (cont’d) 
 
 
Smoking During Pregnancy 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 182 11.6 11.6 21.2 Codes 
1 = Yes 106 6.8 6.8 18.4 
Missing System 1,277 81.6 81.6 100.0  
Total 1,565 100.0 100.0   
 
Race 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 = White Non-Hispanic 927 59.2 59.2 59.2 
  2 = Black Non-Hispanic 343 21.9 21.9 81.2 
  3 = Hispanic 257 16.4 16.4 97.6 
Missing System 38 2.4 2.4  100.0  
Total 1,565 100.0 100.0    
 
Marital Status 
 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Codes 0 = Single, or Living Alone 461 29.5 29.5 29.5 
  1 = Married or Living w/Partner 1,103 70.5 70.5 99.9 
Missing System 1 0.1 0.1  100.0  
Total 1,565 100.0 100.0    
 
Income 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 = < 30K 94 6.0 6.0 6.0 
  2 = 30K – 70K 121 7.7 7.7 13.7 
  3 = > 70K 39 2.5 2.5 16.2 
Missing System 1,311 83.8 83.8  100.0  
Total 1,565 100.0 100.0    
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APPENDIX B Analysis Set 1 (cont’d) 
 
 
Education 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 = < High School 276 17.6 17.6 17.6 
  2 = High School 1,226 78.3 78.3 96.0 
  3 = College/Graduate 63 4.0 4.0 100.0 
Total 1,565 100.0 100.0    
 
Medicare/Medicaid 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0 = No 1,096 70.0 70.0 70.0 
  1 = Yes 464 29.7 29.7 99.7 
Missing System 5 0.3 0.1 100.0  
Total 1,565 100.0 100.0   
 
Foodstamp 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0 = No 235 15.0 15.0 15.0 
  1 = Yes 50 3.2 3.2 3.2 
Missing System 1,280 81.8 81.8 100.0  
Total 1,565 100.0 100.0   
 
AFDC 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0 = No 255 16.3 16.3 16.3 
  1 = Yes 30 1.9 1.9 18.2 
Missing System 1,280 81.8 81.8 100.0  
Total 1,565 100.0 100.0   
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 APPENDIX B Analysis Set 1 (cont’d) 
 
 
Received Prenatal Care 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0 = No 301 19.2 19.2 19.2 
  1 = Yes 1,262 80.6 80.6 99.9 
Missing System 2 0.1 0.1 100.0  
Total 1,565 100.0 100.0   
 
Time Began Prenatal Care 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 = First Trimester 1,190 76.0 76.0 76.0 
  2 = Second Trimester 70 4.5 4.5 80.5 
Missing System 305 19.5 19.5 100.0  
Total 1,565 100.0 100.0   
 
Any Abortion 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 269 17.2 17.2 17.2 
  1 = Yes 16 1.0 1.0 18.2 
Missing System 1,280 81.8 81.8 100.0  
Total 1,565 100.0 100.0   
 
Inject Drugs 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 280 17.9 17.9 17.9 
  1 = Yes 5 0.3 0.3 18.2 
Missing System 1,280 81.8 81.8 100.0  
Total 1,565 100.0 100.0   
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 APPENDIX B Analysis Set 1 (cont’d) 
 
 
Partner Use Drugs 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 264 16.9 16.9 16.9 
  1 = Yes 9 0.6 0.5 17.4 
Missing System 1,292 82.6 82.6 100.0  
Total 1,565 100.0 100.0   
 
Perception that partner had relationship with other females 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 218 13.9 13.9 17.9 
  1 = Yes 55 3.5 3.5 18.2 
Missing System 1,292 82.6 82.6 100.0  
Total 1,565 100.0 100.0   
 
Tested for AIDS 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 191 12.2 12.2 12.2 
  1 = Yes 93 5.9 5.9 18.1 
Missing System 1,281 81.9 81.9 100.0  
Total 1,565 100.0 100.0   
 
Tested for STDs in past 12 mos 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 241 15.4 15.4 15.4 
  1 = Yes 47 3.0 3.0 18.4 
Missing System 1,277 81.6 81.6 100.0  
Total 1,565 100.0 100.0   
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 APPENDIX B Analysis Set 1 (cont’d) 
 
 
Tested or treated for vaginal, UTI, or pelvic infection in past 12 mos 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 199 12.7 12.7 12.7 
  1 = Yes 89 5.7 5.7 18.4 
Missing System 1,277 81.6 81.6 100.0  
Total 1,565 100.0 100.0   
 
Condom use 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 32 2.0 2.0 2.0 
  1 = Yes 256 16.4 16.4 18.4 
Missing System 1,277 81.6 81.6 100.0  
Total 1,565 100.0 100.0   
 
Use rhythm method of birth control 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 219 14.0 14.0 14.0 
  1 = Yes 69 4.4 4.4 18.4 
Missing System 1,277 81.6 81.6 100.0  
Total 1,565 100.0 100.0   
 
 
Been told by MD had hypertension 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 260 16.6 16.6 12.7 
  1 = Yes 28 1.8 1.8 18.4 
Missing System 1,277 81.6 81.6 100.0  
Total 1,565 100.0 100.0   
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 APPENDIX B (cont’d) 
 
 
Analysis Set 2(Adjusted for Primiparity, Gestational Diabetes, and Multiple Gestation 
 
 
Preeclampsia 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 242 71.2 71.2 71.2 
1 = Yes 98 28.8 28.8 100.0 
Codes 
Total 340 100.0 100.0   
 
Age at pregnancy 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 = < 19 years 105 30.9 30.9 30.9 
  2 = 19-34 years 203 59.7 59.7 90.6 
  3 = > 34 years 13 3.8 3.8 94.4 
Missing System 19 5.6 5.6  100.0  
Total 340 100.0 100.0    
 
Genital Warts 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 327 96.2 96.2 96.2 Codes 
1 = Yes 13 3.8 3.8 100.0 
Total 340 100.0 100.0   
 
Gonnorhea 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 335 98.5 98.5 98.5 Codes 
1 = Yes 5 1.5 1.5 100.0 
Total 340 100.0 100.0   
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 APPENDIX B Analysis Set 2 (cont’d) 
 
 
Chlamydia trachomatis 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 321 94.4 94.4 94.4 Codes 
1 = Yes 19 5.6 5.6 100.0 
Total 340 100.0 100.0   
 
Genital Herpes 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 335 98.5 98.5 98.5 Codes 
1 = Yes 5 1.5 1.5 1.5 
Total 340 100.0 100.0   
 
Number of Sexual Partners 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 =  ≤ 1 7 2.1 2.1 2.1 
  2 = 2-3 183 53.8 53.8 55.9 
  3 = 4-5 105 30.9 30.9 86.8 
  4 = > 5 42 12.4 12.4 99.1 
 Missing System 3 0.9 0.9 100.0 
  Total 1,565 100.0 100.0   
 
Frequency of sexual intercourse 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 = ≤ Once/mo 49 14.4 14.4 14.4 
  2 = 2-3/mo 80 23.5 23.5 37.9 
  3 = Once/wk 63 18.5 18.5 56.5 
  4 = 2-3/wk 82 24.1 24.1 80.6 
  5 = ≥ 4/wk 
 21 6.2 6.2 86.8 
Missing System 45 13.2 13.2 100.0 
  Total 188 100.0 100.0   
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 APPENDIX B Analysis Set 2 (cont’d) 
 
 
 
Smoking During Pregnancy 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
0 = No 213 62.7 62.7 62.7 Codes 
1 = Yes 127 37.3 37.3 100.0 
Total 340 100.0 100.0   
 
Race 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 = White Non-Hispanic 243 71.5 71.5 71.5 
  2 = Black Non-Hispanic 77 22.7 22.7 94.1 
  3 = Hispanic 20 5.9 5.9 100.0 
Total 340 100.0 100.0    
 
Marital Status 
 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Codes 0 = Single, or Living Alone 170 50.0 50.0 50.0 
  1 = Married or Living w/Partner 170 50.0 50.0 100.0 
Total 340 100.0 100.0    
 
Income 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 = < 30K 122 35.9 35.9 35.9 
  2 = 30K – 70K 137 40.3 40.3 76.2 
  3 = > 70K 81 23.8 23.8 100.0 
Total 340 100.0 100.0    
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 APPENDIX B Analysis Set 2 (cont’d) 
 
 
 
Education 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 1 = < High School 183 53.8 53.8 53.8 
  2 = High School 157 46.2 46.2 100.0 
Total 340 100.0 100.0    
 
Medicare/Medicaid 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0 = No 231 67.9 67.9 67.9 
  1 = Yes 108 31.8 31.8 99.7 
Missing System 1 0.3 0.3 100.0  
Total 340 100.0 100.0   
 
Foodstamp 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0 = No 267 78.5 78.5 78.5 
  1 = Yes 72 21.2 21.2 99.7 
Missing System 1 0.3 0.3 100.0  
Total 340 100.0 100.0   
 
AFDC 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0 = No 289 85.0 85.0 85.0 
  1 = Yes 50 14.7 14.7 99.7 
Missing System 1 0.3 0.3 100.0  
Total 340 100.0 100.0   
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 APPENDIX B Analysis Set 2 (cont’d) 
 
 
 
Received Prenatal Care 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0 = No 66 19.4 19.4 19.4 
  1 = Yes 274 80.6 80.6 100.0 
Total 340 100.0 100.0   
 
Any Abortion 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 332 97.7 97.7 97.7 
  1 = Yes 8 2.3 2.3 100.0 
Total 340 100.0 100.0   
 
Inject Drugs 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 330 97.1 97.1 97.1 
  1 = Yes 7 2.0 2.0 2.0 
Missing System 3 0.9 0.9 100.0  
Total 340 100.0 100.0   
 
 
Perception that partner had relationship with other females 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 257 75.6 75.6 75.6 
  1 = Yes 68 20.0 20.0 95.6 
Missing System 15 4.4 4.4 100.0  
Total 340 100.0 100.0   
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 APPENDIX B Analysis Set 2 (cont’d) 
 
 
 
Tested for STDs in past 12 mos 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 284 83.5 83.5 83.5 
  1 = Yes 56 16.5 16.5 100.0 
Total 340 100.0 100.0   
 
Tested or treated for vaginal, UTI, or pelvic infection in past 12 mos 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 227 66.8 66.8 66.8 
  1 = Yes 113 33.2 33.2 100.0 
Total 340 100.0 100.0   
 
Condom use 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 37 10.9 10.9 10.9 
  1 = Yes 303 89.1 89.1 100.0 
Total 340 100.0 100.0   
 
Use rhythm method of birth control 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Codes 0= No 262 77.1 77.1 77.1 
  1 = Yes 78 22.9 22.9 100.0 
Total 340 100.0 100.0   
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